Processing math: 28%
Research article Special Issues

A single-cell mathematical model of SARS-CoV-2 induced pyroptosis and the effects of anti-inflammatory intervention

  • Both authors contributed equally to this work
  • Pyroptosis is an inflammatory mode of cell death that can contribute to the cytokine storm associated with severe cases of coronavirus disease 2019 (COVID-19). The formation of the NLRP3 inflammasome is central to pyroptosis, which may be induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Inflammasome formation, and by extension pyroptosis, may be inhibited by certain anti-inflammatory drugs. In this study, we present a single-cell mathematical model that captures the formation of the NLRP3 inflammasome, pyroptotic cell death and responses to anti-inflammatory intervention that hinder the formation of the NLRP3 inflammasome. The model is formulated in terms of a system of ordinary differential equations (ODEs) that describe the dynamics of the key biological components involved in pyroptosis. Our results demonstrate that an anti-inflammatory drug can delay the formation of the NLRP3 inflammasome, and thus may alter the mode of cell death from inflammatory (pyroptosis) to non-inflammatory (e.g., apoptosis). The single-cell model is implemented within a SARS-CoV-2 tissue simulator, in collaboration with a multidisciplinary coalition investigating within host-dynamics of COVID-19. In this paper, we additionally provide an overview of the SARS-CoV-2 tissue simulator and highlight the effects of pyroptosis on a cellular level.

    Citation: Sara J Hamis, Fiona R Macfarlane. A single-cell mathematical model of SARS-CoV-2 induced pyroptosis and the effects of anti-inflammatory intervention[J]. AIMS Mathematics, 2021, 6(6): 6050-6086. doi: 10.3934/math.2021356

    Related Papers:

    [1] Gauhar Rahman, Iyad Suwan, Kottakkaran Sooppy Nisar, Thabet Abdeljawad, Muhammad Samraiz, Asad Ali . A basic study of a fractional integral operator with extended Mittag-Leffler kernel. AIMS Mathematics, 2021, 6(11): 12757-12770. doi: 10.3934/math.2021736
    [2] Pshtiwan Othman Mohammed, Rajendra Dahal, Christopher S. Goodrich, Y. S. Hamed, Dumitru Baleanu . Analytical and numerical negative boundedness of fractional differences with Mittag–Leffler kernel. AIMS Mathematics, 2023, 8(3): 5540-5550. doi: 10.3934/math.2023279
    [3] Manal Alqhtani, Khaled M. Saad . Numerical solutions of space-fractional diffusion equations via the exponential decay kernel. AIMS Mathematics, 2022, 7(4): 6535-6549. doi: 10.3934/math.2022364
    [4] Khaled M. Saad, Manal Alqhtani . Numerical simulation of the fractal-fractional reaction diffusion equations with general nonlinear. AIMS Mathematics, 2021, 6(4): 3788-3804. doi: 10.3934/math.2021225
    [5] Mohra Zayed, Maged G. Bin-Saad, Waleed K. Mohammed . On Mittag-Leffler-Gegenbauer polynomials arising by the convolution of Mittag-Leffler function and Hermite polynomials. AIMS Mathematics, 2025, 10(7): 16642-16663. doi: 10.3934/math.2025746
    [6] Abdul Qadeer Khan, Fakhra Bibi, Saud Fahad Aldosary . Bifurcation analysis and chaos in a discrete Hepatitis B virus model. AIMS Mathematics, 2024, 9(7): 19597-19625. doi: 10.3934/math.2024956
    [7] Dong-Mei Li, Bing Chai . A dynamic model of hepatitis B virus with drug-resistant treatment. AIMS Mathematics, 2020, 5(5): 4734-4753. doi: 10.3934/math.2020303
    [8] Weerawat Sudsutad, Jutarat Kongson, Chatthai Thaiprayoon, Nantapat Jarasthitikulchai, Marisa Kaewsuwan . A generalized Gronwall inequality via ψ-Hilfer proportional fractional operators and its applications to nonlocal Cauchy-type system. AIMS Mathematics, 2024, 9(9): 24443-24479. doi: 10.3934/math.20241191
    [9] Hari M. Srivastava, Artion Kashuri, Pshtiwan Othman Mohammed, Abdullah M. Alsharif, Juan L. G. Guirao . New Chebyshev type inequalities via a general family of fractional integral operators with a modified Mittag-Leffler kernel. AIMS Mathematics, 2021, 6(10): 11167-11186. doi: 10.3934/math.2021648
    [10] Naveed Shahid, Muhammad Aziz-ur Rehman, Nauman Ahmed, Dumitru Baleanu, Muhammad Sajid Iqbal, Muhammad Rafiq . Numerical investigation for the nonlinear model of hepatitis-B virus with the existence of optimal solution. AIMS Mathematics, 2021, 6(8): 8294-8314. doi: 10.3934/math.2021480
  • Pyroptosis is an inflammatory mode of cell death that can contribute to the cytokine storm associated with severe cases of coronavirus disease 2019 (COVID-19). The formation of the NLRP3 inflammasome is central to pyroptosis, which may be induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Inflammasome formation, and by extension pyroptosis, may be inhibited by certain anti-inflammatory drugs. In this study, we present a single-cell mathematical model that captures the formation of the NLRP3 inflammasome, pyroptotic cell death and responses to anti-inflammatory intervention that hinder the formation of the NLRP3 inflammasome. The model is formulated in terms of a system of ordinary differential equations (ODEs) that describe the dynamics of the key biological components involved in pyroptosis. Our results demonstrate that an anti-inflammatory drug can delay the formation of the NLRP3 inflammasome, and thus may alter the mode of cell death from inflammatory (pyroptosis) to non-inflammatory (e.g., apoptosis). The single-cell model is implemented within a SARS-CoV-2 tissue simulator, in collaboration with a multidisciplinary coalition investigating within host-dynamics of COVID-19. In this paper, we additionally provide an overview of the SARS-CoV-2 tissue simulator and highlight the effects of pyroptosis on a cellular level.



    Hepatitis is an inflammatory liver disease caused by excessive alcohol consumption, pollutants, drugs, and health issues. Hepatitis B, the most dangerous form, is responsible for 600,000 annual deaths from acute or chronic complications, making it a significant global healthcare issue [1]. Hepatitis B virus (HBV) is a DNA virus from the Hepadnaviridae family, first identified in an Australian aborigine. It causes severe liver illnesses, targeting hepatocytes. HBV's unique genomic DNA undergoes a molecular template DNA transformation, generating a viral RNA intermediate and reverse-transcribed back into viral DNA. This stable DNA causes perpetual infection and low recovery rates. The complex HBV life cycle has led to the development of antiviral medicines [2]. Chronic HBV infection affects 580,000-2.4 million US citizens, increasing the risk of liver cancer and cirrhosis. 69% of the population, particularly non-US citizens, have the virus, particularly during perinatal periods. Despite successful hepatitis B vaccination, 70% of US residents self-reported not receiving it in 2018. Antiviral medication, tracking, and liver cancer diagnosis can help reduce mortality and morbidity [3]. Hepatocellular carcinoma (HCC) and liver cirrhosis are diseases caused by the hepatitis B virus. Prevention is crucial, with the first cancer vaccine being the HBV vaccine. The World Health Organization proposes a 90% vaccination goal to eradicate hepatitis B by 2030, making HCC prevention a key part of medical policy [4].

    For researchers and policy advisers, mathematical modeling is a critical tool for gathering and assessing data from experiments for medical interventions. It combines data from a variety of sources into a coherent structure, enabling an in-depth examination of challenging issues. The consequences of treatments are simulated by mathematical models, which also offer quantitative forecasts for potential population wellness effects. It has a lengthy history and has developed into a crucial instrument for making decisions in the fight against infectious diseases [5,6,7,8]. To forecast HBV transmission dynamics and assess a prolonged period efficacy of China's vaccination initiative, Zhao et al. [9] created a mathematical model. By creating wave movement using geometrically distinct perturbation and permitting non-monotone propagating characteristics by numerical simulations, the model developed in [10] simulates HBV infection with spatial dependency. Two treatment-related hepatitis C virus (HCV) models were observed by Martin et al. [11] who discovered various bifurcation patterns. They computed analytical answers for the medication levels required for disease eradication or control and discovered that reachable levels may culminate in control or extinction over diverse prevalence levels. In [12], researchers put out an HBV infection model including vaccine and treatment, evaluating dynamic behavior for uniform controls and applying Pontryagin's maximal concept to solve optimal control concerns. The use of mixed control strategies outperformed independent controls, according to numerical findings. The dynamics of HBV are greatly influenced by surroundings like humidity and environmental temperature. In a study [13], An effective approach for identifying these implications is stochastic modeling. A stochastic hepatitis B model that takes into account the transmission coefficient's time delay and the Cytotoxic T cells (CTL) immune response class has been constructed. Wodajo et al. [14] developed a nonlinear mathematical model for the kinetics of HBV transmission while taking into account the impacts of immunization, medication, migration, and screening.

    Mathematical analysis techniques that use fractional calculus to extend differential equations are referred to as fractional differential equations. They are useful in biological contexts because of their intrinsic affinity for memory-based systems, and they are frequently incorporated into epidemiological models [15,16,17,18,19], which makes them an important resource for comprehending complicated systems. In science, especially physics and engineering [20,21,22,23,24], fractional calculus is frequently employed. Fractional order models are considered more realistic and practical than traditional ordinal order models due to the use of fractional differential equations to differentiate between distinct mathematical models' hereditary and data storage properties. Two models for hepatitis B were presented by Cardoso et al. [25], both of which had their foundations on fractional differential equations. Drug therapy factors were absent from the first model whereas they were included in the second. Both models took stability analysis and reproduction number into account, and numerical simulations utilizing unconventional finite difference methods revealed that the solutions tend to an equilibrium point. Khan et al. [26] studied the kinetics of HIV using the Caputo-Fabriizo derivative, utilizing the hypothesis of fixed points to get conclusions on uniqueness, and using the Adams-Bashfirth numerical approach to solve the problem. Using the Atangana-Baleanu derivative in Caputo sense, mathematicians created a new epidemic fractional order model to describe HBV in [27]. A two-step Lagrange polynomial-based iterative approach was used to determine the solution after the model's nonnegativity, distinction, reproduction number, and equilibria were assessed. Utilizing the Caputo-Fabrizio fractional derivative with immunological delay, Gao et al. [28] presented a mathematical model regarding the HBV. Applying the Laplace transform and fixed point theorem, the model's singularity was established. The iterative solutions' stability was examined using the Sumudu transform and Picard iteration. In the study [29], Lévy noise-driven HBV infection is analyzed, taking into account the influence of vaccination on the dynamics of the epidemic. It employs a non-integer order, fractal dimension fractional-order scheme. To examine the stochastic model, the theoretical analysis employs the Lyapunov function. In order to conduct additional research and validate the findings, numerical simulations and correlations with deterministic structures were offered. Several numerical techniques for analyzing fractional differential equations have been suggested during the last few decades, with the finite difference and finite element methods serving as the primary instruments. Meshless or mesh-free approaches have recently emerged for studying science and engineering problems, with the problem area represented as a cloud of distributed points [30].

    In view of their unique properties, enhanced fractional continuous and discrete operators utilizing Mittag-Leffler kernels are especially interesting as discrete equivalents [31,32,33]. Employing an improved Atangana-Baleanu fractional difference operator, Farman et al. [34] created a fractional-order representation of Bovine Brucellosis. They evaluated the global stability of the Volterra-type Lyapunov function and applied the Lipschitz criterion to guarantee originality. For numerical simulations and emphasizing the consequences of the illness caused by different causes, solutions were generated in the discrete generalized version [35]. They conducted assessment using fixed point approaches, looked at the stability of the solution in the Hyers-Ulam meaning, and applied iterative approaches to get an imprecise answer in series. This paper suggests a rarely discussed fractional order model with discrete generalized Mittag-Leffler kernels for the dynamics of HBV. It will also serve as a basis for numerous dynamical problems including their existence, distinctiveness, and numerical simulations.

    Here are some essential definitions that you may find helpful in system analysis.

    Definition 2.1. [31,36] Consider the reversed jump operator to be (t)=t1.

    The nabla left fractional sum of order σ>0 is defined considering a function X:Nj={j,j+1,j+2,...}R as

    jσ[X(t)]=1Γ(σ)tω=σ+1X(ω)[t(ω)]¯σ1,tNj+1. (2.1)

    The nabla left fractional difference of order σ>0 is defined by

    jσ[X(t)]=k(kσ)jX(t)=kΓ(kσ)tω=σ+1X(ω)[t(ω)]¯kσ1,tNj+1. (2.2)

    The nabla left fractional sum of order σ>0 is defined considering a function X:pN={p,p1,p2,...}R as

    σp[X(t)]=1Γ(σ)p1ω=tX(ω)[ω(t)]¯σ1,tp1N. (2.3)

    The nabla left fractional difference of order σ>0 is defined by

    σp[X(t)]=Δk(kσ)pX(t)=(1)kΔkΓ(kσ)p1ω=tX(ω)[ω(t)]¯kσ1,tp1N. (2.4)

    Definition 2.2. [31,37] For ψR:|ψ|<1, and σ,υ,γC with Re(σ)>0, the nabla discrete Mittag-leffler function of three parameters is defined as:

    Eγ¯σ,υ(ψ,t)=k=0ψk t¯kσ+υ1(γ)kk!Γ(kσ+υ),(γ)k=γ(γ+1)...(γ+k1). (2.5)

    For γ=1, we can calculate the discrete Mittag-Leffler function of two parameters as

    E1¯σ,υ(ψ,t)=E¯σ,υ(ψ,t)=k=0ψk t¯kσ+υ1(1)kk!Γ(kσ+υ)=k=0ψk t¯kσ+υ1Γ(kσ+υ). (2.6)

    For γ=υ=1, the discrete Mittag-Leffler function of one parameter is determined by

    E¯σ(ψ,t)=k=0ψkt¯kσΓ(kσ+1). (2.7)

    Remark 2.1. For, ψ=σ1σ and σ(0,12), the initial values of E¯σ(ψ,t) at t=0,1,2, and 3 are as follows, taken from [38]:

    {E¯σ(ψ,0)=1,E¯σ(ψ,1)=1σ,E¯σ(ψ,2)=(1σ)2(1+σ),E¯σ(ψ,3)=1σ2((2σ1)σ33σ2+2). (2.8)

    Overall, it is evident that

    0<E¯σ(ψ,t)<1,t=1,2,3,.. (2.9)

    Conversely, we have that for each t=0,1,2,..., E¯σ(ψ,t) is monotonically decreasing.

    Lemma 2.3. [31,37] The discrete Laplace transform () of a function X defined on Nj (2.1) can be expressed by

    [jX(t)](ω)=t=j+1X(t)(1ω)jt+1. (2.10)

    Let Z be a function also defined on Nj, then the discrete Laplace transform of convolution of X and Z is given by

    [j(XZ)(t)](ω)=(jX)(ω)×(jZ)(ω). (2.11)

    Lemma 2.4. [31,37] For a function X defined on Nj, the outcome is as stated below.

    [j[X(t)]](ω)=ω(jX(t))(ω)X(j). (2.12)

    In general,

    [j[kX(t)]](ω)=ωk(jX(t))(ω)k1r=0ω(kr1) r X(j+1). (2.13)

    Lemma 2.5. [31,32,39] Specify a real number as σ. Then, we have

    [j[RLjσX(t)]](ω)=1ωσ(jX(t))(ω). (2.14)

    Lemma 2.6. [31,32,39] For σ,υ,ψ,ωC with Re(υ)>0, we have

    [σE¯σ,υ(ψ,tj)](ω)=1ωυ(1ψωσ), (2.15)

    if |ψωσ|<1 with Re(ω)>0. Also, we can find

    [σE¯σ,σ(ψ,tj)](ω)=1ωσψ. (2.16)

    Definition 2.7. [31,32,39] Assume that X is defined on NjpN, j<p. Then, for ψ=σ1σ and 0<σ<12, the left discrete generalized Atangana-Baleanu of the Liouville-Caputo sense fractional difference is given by

    abjσ[X(t)]=ab(σ)1σtω=j+1X(ω)E¯σ(ψ,t+1ω),  tNj, (2.17)

    where ab(σ)>0 with ab(σ)|0,1=1 is a normalization function. Additionally, the fractional difference of the Liouville-Caputo type right discrete generalized Atangana-Baleanu is described by

    abσp[X(t)]=ab(σ)1σp1ω=tΔX(ω)E¯σ(ψ,t+1ω),  tpN. (2.18)

    The definition of the left discrete Atangana-Baleanu fractional sum is

    abjσ[X(t)]=1σab(σ)X(t)+σab(σ)jσ[X(t)],  tNj. (2.19)

    Definition 2.8. [39] Assume that X is defined on NjpN, j<p. Then, for ψ=σ1σ and 0<σ<12, the we have

    mabcjσ[X(t)]=ab(σ)1σ(X(t)E¯σ(ψ,tj)X(j)+ψtω=j+1E¯σ,σ(ψ,t+1ω)X(ω)),  tNj. (2.20)

    Furthermore, the fractional difference of the right discrete Atangana-Baleanu modified Liouville-Caputo type is provided by

    mabcσp[X(t)]=ab(σ)1σ(X(t)E¯σ(ψ,pt)X(p)+ψp1ω=tE¯σ,σ(ψ,ω+1t)X(ω)),  tpN. (2.21)

    The outcomes listed below can be drawn by generalizing using the approach as for σ(0,1).

    Definition 2.9. [39] Assume that wN0, then for ψw=σww+1σ and σ(w,w+12), the left discrete modified Atangana-Baleanu of the Liouville-Caputo sense fractional difference of a higher order is given by

    mabcjσX(t)=mabcjσwwX(t)=ab(σw)w+1σ[wX(t)X(j)E¯σw(ψw,tj)w+ψwtω=j+1X(ω)E¯σw,σw(ψw,t+1ω)w],tNj. (2.22)

    Also, the right discrete modified Atangana-Baleanu of the Liouville-Caputo type fractional difference of a higher order is given by

    mabcσpX(t)=mabcσwpwX(t)=ab(σw)w+1σ[wX(t)X(p)E¯σw(ψw,pt)w+ψwp1ω=tX(ω)E¯σw,σw(ψw,ω+1t)w],tpN. (2.23)

    In this section, we look at a SEACTR epidemic model [1], which divides the entire population into six time-associated classes according to the form of HBV disease:

    ● Susceptible class (S): A susceptible individual is one who lacks immunization or has compromised immunity, permitting the virus to penetrate into the body and get into tissues, replicate, and trigger a reaction, potentially leading to HBV infection if subjected to transmission techniques.

    ● Exposed class (E): Individuals who have contracted infection but are yet to become contagious are classified as exposed.

    ● Acute infective class (A): Acute infective pertains to people who have been hosts of microorganisms for no longer than six months and who are actively spreading or transmitting HBV or who have the ability of doing so.

    ● Chronic infective class (C): Chronic infectious ailments are caused by HBV that continue to exist after a first infection, frequently leading to recurring or chronic illnesses that affect people who seem healthy but are actually harboring infections.

    ● Treated class (T): People who receive lamivudine, tenofovir, and various other therapies after developing a chronic infection are believed to be in the treated class.

    ● Recovered class (R): People in the recovered class have either had successful medical treatment or have recovered naturally.

    Mathematical models with fractional derivatives provide more flexibility when analyzing memory effects and illness dynamics on particular datasets. Hence, the new fractional-order HBV model is developed using the nonlinear fractional differential equations listed below under the left discrete modified Atangana-Baleanu of the Liouville-Caputo type fractional derivative with 0<σ<12.

    {mabcjσS(t)=κκβ1CκϑR+κ2R[ηλ(A+ξC)+κ+α]S,mabcjσE(t)=ηλ(A+ξC)S(η1+η2+κ)E,mabcjσA(t)=η1E(δ1+δ2+κ)A,mabcjσC(t)=η2E+δ1A(ϕ+ζ+κκβ1)C,mabcjσT(t)=ϕC(χ+κ)T,mabcjσR(t)=χT+δ2A+αS+(κϑκκ2)R (3.1)

    with nonnegative initial constraints,

    S(0)=S00,E(0)=E00,A(0)=A00,C(0)=C00,T(0)=T00,R(0)=R00. (3.2)

    Susceptible group increases with the arrival of birth flux rate κκβ1CκϑR. The natural birth/death rate is expressed as κ. For the purpose of vertical transmission, we suppose that a certain percentage, β1, of newborns from infected classes are infected. This percentage is represented by the term κβ1C,(β<1). Where ϑ,(ϑ<1), is used to indicate that a certain percentage of newborns from the recovered class are immunized. Immune response degradation rate of the recovered class is represented by κ2. The phrase ηλ(A+ξC)S is used to describe the force of HBV infection, where η is the per capita interaction rate, λ is the likelihood of contracting HBV infection from a single infected person, and ξ is the contamination level of the chronic infected group (C). The rate of immunization causes proportions of susceptible people to transfer to recovered classes at a rate of α. The rate at which susceptible people become chronic HBV carriers is termed η1. The rate of transmission from exposed to acutely infected persons is defined as η2. δ1 represents the rate at people gradually become chronic HBV carriers and δ2 represents the rate at which people who are acutely which infected recover from the disease naturally. The rate of chronically infected people seeking treatment is ϕ, the rate of HBV disease-related deaths is ζ, and the rate of treatment class recovery is χ. It is also assumed that the number of newborn carriers is less than the total number of carriers who will die and those who will move from carriers to recovery states. We illustrate it in Figure 1.

    Figure 1.  Hepatitis B epidemic model considering Susceptible (S), Exposed (E), Acute (A), Chronic (C), Treated (T), and Reovered (R) populations.

    Here we investigate the circumstances that, under the assumption that real-world conditions with pertinent values are present, ensure that the solutions of the proposed model are positive. For this purpose, we find

    {E(t)E0e(η1+η2+κ)t,A(t)A0e(δ1+δ2+κ)t,C(t)C0e(ϕ+ζ+κκβ1)t,T(t)T0e(χ+κ)t,R(t)R0e(κϑκκ2)t, (4.1)

    for all t0.

    We specify norm for the class S:

    P=suptDP|P(t)|, (4.2)
    mabcjσS(t)=κκβ1CκϑR+κ2R[ηλ(A+ξC)+κ+α]S,mabcjσS(t)[ηλ(A+ξC)+κ+α]S,mabcjσS(t)[ηλ(suptDA|A|+ξsuptDC|C|)+κ+α]S,mabcjσS(t)[ηλ(|A|+ξ|C|)+κ+α]S. (4.3)

    We can conclude that

    S(t)S0e(ηλ(|A|+ξ|C|)+κ+α)t   ,   t0. (4.4)

    The positively invariant set of a dynamical system is defined as one in which the system always stays in the set after emitting from it. We construct a positively invariant region that is closed curve-bounded and encircles the origin.

    Theorem 4.1. In straightforward settings, the suggested model (3.1)'s solution is singular and constrained to R6+.

    Proof. We shall demonstrate the system (3.1)'s positive solution, and the outcomes are given as follows:

    mabcjσS(t)|S=0=κκβ1CκϑR+κ2R0,mabcjσE(t)|E=0=ηλ(A+ξC)S0,mabcjσA(t)|A=0=η1E0,mabcjσC(t)|C=0=η2E+δ1A0,mabcjσT(t)|T=0=ϕC0,mabcjσR(t)|R=0=χT+δ2A+αS0. (4.5)

    The solution cannot evacuate the hyperplane if (S0,E0,A0,C0,T0,R0)R5+. The domain R6+ is a positivity invariant set. The following total population is obtained by summing each part of the model (3.1)'s population:

    mabcjσN(t)=mabcjσS(t)+mabcjσE(t)+mabcjσA(t)+mabcjσC(t)+mabcjσT(t)+mabcjσR(t)=κζCκ(S+E+A+C+T+R) κκN. (4.6)
    N(0)1N(t)1.

    Therefore, a solution of the fractional model (3.1) exists in M for all t>0. As such, the suggested HBV model is mathematically and epidemiologically well-posed. Therefore, it is sufficient to examine the fundamental model's dynamics in the feasible region:

    M={(S,E,A,C,T,R)R6+:N(t)1}. (4.7)

    The following total population is obtained by summing each part of the model (3.1)'s population:

    N(t)=S(t)+E(t)+A(t)+C(t)+T(t)+R(t). (4.8)

    We can write

    1(S(t)+E(t)+A(t)+C(t)+T(t))=R(t). (4.9)

    Hence, our proposed system reduces to

    {mabcjσS(t)=κκβ1C+(κ2κϑ)(1SEACT)[ηλ(A+ξC)+κ+α]S,mabcjσE(t)=ηλ(A+ξC)S(η1+η2+κ)E,mabcjσA(t)=η1E(δ1+δ2+κ)A,mabcjσC(t)=η2E+δ1A(ϕ+ζ+κκβ1)C,mabcjσT(t)=ϕC(χ+κ)T. (4.10)

    We employ E=A=C=0 to get the HBV-free equilibrium point (E) of system (4.10). We obtain

    E={S,E,A,C,T}={κ(1ϑ)+κ2κ(1ϑ)+κ2+α,0,0,0,0} (4.11)

    The system (4.10)'s endemic equilibrium point is indicated by E:

    E={S,E,A,C,T}

    where,

    S=(κ+η1)(κ+η2)(κ(1β1)+δ2+κ2)ηλ(κ(1β1)+δ1+δ2+κ2)η1,E=ηλS(A+ξC)κ+η1+η2,A=ηλη1ξCS1ηλη1S,C=ηλη2S(A+ξC)(κ+η1+η2)(κ(1β1)+ζ+ϕ)+ηλη1δ1ϑCS(1ηλη1S)(κ(1β1)+ϕ),T=[ηλη2S(A+ξC)(κ+η1+η2)(κ(1β1)+ϕ)+ηλη1δ1ξCS(1ηλη1S)(κ(1β1)+ϕ)](ακ+χ). (4.12)

    It is well recognized that a disease's ability to spread or remain within a community is based on its basic reproductive number. Utilizing the next generation matrix approach on (4.10), we get the reproductive number (\mathscr{R}_0) . where

    \begin{equation} \mathscr{R}_0 = \frac{\eta\lambda\big(\kappa(1-\vartheta)+\kappa_2\big)\Big[\eta_1(\kappa+\eta_1+\eta_2+\delta_1\xi)+\xi\eta_2\big(\kappa(1-\beta_1)+\zeta+\phi\big)\Big]}{ \big(\kappa(1-\vartheta)+\kappa_2+\alpha\big)(\kappa+\eta_1+\eta_2)(\kappa+\delta_1+\delta_2)\big(\kappa(1-\beta_1)+\kappa_2\big)}. \end{equation} (4.13)

    In fact, the HBV will die out, and there will be no epidemic when \mathscr{R}_0 < 1 . In the meantime, an epidemic will develop if \mathscr{R}_0 > 1 . Furthermore, the \mathscr{R}_0 value shows how contagious the HBV disease is.

    It is possible to reduce or regulate the incidence and prevalence of HBV if the key effects of each parameter in the dynamics of the illness are taken into account. It investigates the impact of each parameter on the fundamental reproduction number \mathscr{R} . The sensitivity indices for each parameter are listed in the table below (see Table 1).

    Table 1.  Reproductive number's parameters sensitivity indices [1].
    Parameter Index Parameter Index Parameter Index
    \eta +1 \eta_1 +1.3769 \eta_2 +1.4761
    \delta_1 -0.7338 \delta_2 -0.5968 \vartheta -1.3287
    \kappa +0.3647 \kappa_2 +0.3297 \xi +0.9138
    \chi -0.4286 \alpha +0.3593 \phi -1.0025
    \lambda +1 \zeta +0.3748 \beta_1 +0.33593

     | Show Table
    DownLoad: CSV

    Systems and control theory heavily relies on the stability analysis of equilibrium points, which are defined by the Lyapunov function. It facilitates the evaluation of equilibrium points' asymptotic stability in both linear and nonlinear systems without the need to explicitly calculate the differential equation's solution. The asymptotic stability of a scalar positive definite function with a negative definite time derivative is known. For identifying infection stages and creating disease management plans, the global stability study of epidemiological algorithms is essential. In terms of disease prevention, the Volterra-Lyapunov matrix theory has become more popular. In order to investigate the global stability of the proposed system, this study compares the stability of risk endemic equilibrium with disease-free equilibrium globally.

    Lemma 4.1. [40] Let \mathcal{U}(t)\in\mathbb{R}^{+} be a continuous function such that

    \begin{equation} {}_{t_0}^{mabc}\nabla^{\sigma}\Big(\mathcal{U}(t)-\mathcal{U}^{*}-\mathcal{U}^{*}\ln\frac{\mathcal{U}(t)}{\mathcal{U}^{*}}\Big)\leq\Big(1-\frac{\mathcal{U}^{*}}{ \mathcal{U}(t)} \Big)[\; {}^{mabc}_{t_0}\nabla^{\sigma}\mathcal{U}(t)],\; \; \; \; \; \; \; \forall t\geq t_0, \end{equation} (4.14)

    \mathcal{U}^{*}\in\mathbb{R}^{+}, \forall \sigma\in(0, \frac{1}{2}) .

    Theorem 4.2. The HBV-free equilibrium states (\mathfrak{E}^{\diamond}) are globally asymptotically stable provided the reproductive number (\mathscr{R}) is less than 1.

    Proof. Define a Volterra-type Lyaponuv function (\mathcal{V}) by

    \begin{align} \mathcal{V} = \Big({\mathbf{S}}-{\mathbf{S}}^{\diamond}-{\mathbf{S}}^{\diamond}\ln\frac{{\mathbf{S}}}{{\mathbf{S}}^{\diamond}}\Big) + {\mathbf{E}} +{\mathbf{A}}+{\mathbf{C}}+{\mathbf{T}}. \end{align} (4.15)

    Using Lemma 4.1, we get

    \begin{align} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{V}\leq \Big(1-\frac{{\mathbf{S}}^{\diamond}}{{\mathbf{S}}}\Big) [\ {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{S}} ] +[\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{E}}]+[\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{A}}] +[\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{C}}] +[\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{T}}]. \end{align} (4.16)

    When we substitute the derivative values from (4.10), we discover

    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{V}\; \leq\; &\Big(1-\frac{{\mathbf{S}}^{\diamond}}{{\mathbf{S}}}\Big) \Big\{\kappa-\kappa\beta_1{\mathbf{C}}+(\kappa_2-\kappa\vartheta)\big(1-{\mathbf{S}}-{\mathbf{E}}-{\mathbf{A}}-{\mathbf{C}} -{\mathbf{T}}\big) -\big[\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}})+\kappa+\alpha\big]{\mathbf{S}}\Big\} \\ & +\Big\{\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}}){\mathbf{S}}-(\eta_1+\eta_2+\kappa){\mathbf{E}}\Big\}+\Big\{\eta_1{\mathbf{E}}-(\delta_1+\delta_2+\kappa){\mathbf{A}}\Big\}\\ & +\Big\{\eta_2{\mathbf{E}}+\delta_1{\mathbf{A}}-(\phi+\zeta+\kappa-\kappa\beta_1){\mathbf{C}}\Big\}+\Big\{\phi{\mathbf{C}}-(\chi+\kappa){\mathbf{T}}\Big\}. \end{split} \end{equation} (4.17)

    Let {\mathbf{S}} = {\mathbf{S}}-{\mathbf{S}}^{\diamond} , {\mathbf{E}} = {\mathbf{E}}-{\mathbf{E}}^{\diamond} , {\mathbf{A}} = {\mathbf{A}}-{\mathbf{A}}^{\diamond} , {\mathbf{C}} = {\mathbf{C}}-{\mathbf{C}}^{\diamond} , and {\mathbf{T}} = {\mathbf{T}}-{\mathbf{T}}^{\diamond} , then we find

    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{V}\; \leq\; & \Big(1-\frac{{\mathbf{S}}^{\diamond}}{{\mathbf{S}}}\Big) \Big\{\kappa-\kappa\beta_1({\mathbf{C}}-{\mathbf{C}}^{\diamond}) +(\kappa_2-\kappa\vartheta)\big(1-({\mathbf{S}}-{\mathbf{S}}^{\diamond})-({\mathbf{E}}-{\mathbf{E}}^{\diamond})-({\mathbf{A}}-{\mathbf{A}}^{\diamond}) \\ &-({\mathbf{C}}-{\mathbf{C}}^{\diamond})-({\mathbf{T}}-{\mathbf{T}}^{\diamond})\big)-\big[\eta\lambda(({\mathbf{A}}-{\mathbf{A}}^{\diamond})+\xi({\mathbf{C}}-{\mathbf{C}}^{\diamond})) +\kappa+\alpha\big]({\mathbf{S}}-{\mathbf{S}}^{\diamond}) \Big\} \\ & +\Big\{\eta\lambda(({\mathbf{A}}-{\mathbf{A}}^{\diamond})+\xi({\mathbf{C}}-{\mathbf{C}}^{\diamond}))({\mathbf{S}}-{\mathbf{S}}^{\diamond})-(\eta_1+\eta_2+\kappa)({\mathbf{E}}-{\mathbf{E}}^{\diamond})\Big\}\\ &+ \Big\{\eta_1({\mathbf{E}}-{\mathbf{E}}^{\diamond})-(\delta_1+\delta_2+\kappa)({\mathbf{A}}-{\mathbf{A}}^{\diamond})\Big\} \\ &+\Big\{\eta_2({\mathbf{E}}-{\mathbf{E}}^{\diamond}) +\delta_1({\mathbf{A}}-{\mathbf{A}}^{\diamond})-(\phi+\zeta+\kappa-\kappa\beta_1)({\mathbf{C}}-{\mathbf{C}}^{\diamond})\Big\}\\ &+\Big\{\phi({\mathbf{C}}-{\mathbf{C}}^{\diamond}) -(\chi+\kappa)({\mathbf{T}}-{\mathbf{T}}^{\diamond})\Big\}. \end{split} \end{equation} (4.18)

    As we can see, for

    \mathscr{R} < 1\; \; \; \; \; \Rightarrow\; \; \; \; {}_{a}^{MABC}\nabla^{\sigma}\mathcal{V}\leq 0,

    and {}_{a}^{MABC}\nabla^{\sigma}\mathcal{V} = 0 only when

    {\mathbf{S}} = {\mathbf{S}}^{\diamond},\; \; {\mathbf{E}} = {\mathbf{E}}^{\diamond},\; \; {\mathbf{A}} = {\mathbf{A}}^{\diamond},\; \; {\mathbf{C}} = {\mathbf{C}}^{\diamond},\; \; {\mathbf{T}} = {\mathbf{T}}^{\diamond}.

    Thus, we draw the conclusion that global asymptotically stable HBV-free equilibrium states (\mathfrak{E}^{\diamond}) exist.

    For the endemic Lyapunov function, we assign all independent variables to the suggested model.

    Theorem 4.3. The endemic equilibrium points (\mathfrak{E}^{\bullet}) are globally asymptotically stable if the calculation of reproduction number (\mathscr{R}_0) is greater than 1.

    Proof. Define a Volterra-type Lyaponuv function (\mathcal{X}) by

    \begin{eqnarray} \mathcal{X} & = & {\rho}_1\Big({\mathbf{S}}-{\mathbf{S}}^{\bullet}-{\mathbf{S}}^{\bullet}\ln\frac{{\mathbf{S}}}{{\mathbf{S}}^{\bullet}}\Big) + {\rho}_2\Big({\mathbf{E}}-{\mathbf{E}}^{\bullet}-{\mathbf{E}}^{\bullet}\ln\frac{{\mathbf{E}}}{{\mathbf{E}}^{\bullet}}\Big) + {\rho}_3\Big({\mathbf{A}}-{\mathbf{A}}^{\bullet}-{\mathbf{A}}^{\bullet}\ln\frac{{\mathbf{A}}}{{\mathbf{A}}^{\bullet}}\Big) \\ &{}& +{\rho}_4\Big({\mathbf{C}}-{\mathbf{C}}^{\bullet}-{\mathbf{C}}^{\bullet}\ln \frac{{\mathbf{C}}}{{\mathbf{C}}^{\bullet}}\Big) + {\rho}_5\Big({\mathbf{T}}-{\mathbf{T}}^{\bullet}-{\mathbf{T}}^{\bullet}\ln\frac{{\mathbf{T}}}{{\mathbf{T}}^{\bullet}}\Big). \end{eqnarray} (4.19)

    where \rho_i, \; i = 1, 2, 3, 4, 5, 6 are future-selectable positive constants. Using Lemma 4.1 and the Eq (4.19) to replace system (4.10), we discover

    \begin{eqnarray} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{X} & \leq & {\rho}_1(\frac{{\mathbf{S}}-{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}) [\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{S}} ] + {\rho}_2(\frac{{\mathbf{E}}-{\mathbf{E}}^{\bullet}}{{\mathbf{E}}}) [\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{E}}]+ {\rho}_3(\frac{{\mathbf{A}}-{\mathbf{A}}^{\bullet}}{{\mathbf{A}}}) [\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{A}}] \\ &{}& + {\rho}_4(\frac{{\mathbf{C}}-{\mathbf{C}}^{\bullet}}{{\mathbf{C}}}) [\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{C}}] + {\rho}_5(\frac{{\mathbf{T}}-{\mathbf{T}}^{\bullet}}{{\mathbf{T}}}) [\; {}_{j}^{mabc}\nabla^{\sigma}{\mathbf{T}}]. \end{eqnarray} (4.20)

    Substituting the related derivative values from (4.10), we get

    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{X}\; \leq\; & {\rho}_1\Big(1-\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}\Big) \Big\{\kappa-\kappa\beta_1{\mathbf{C}}+(\kappa_2-\kappa\vartheta)\big(1-{\mathbf{S}}-{\mathbf{E}}-{\mathbf{A}}-{\mathbf{C}} -{\mathbf{T}}\big) -\big[\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}})+\kappa+\alpha\big]{\mathbf{S}}\Big\} \\ & + {\rho}_2\Big(1-\frac{{\mathbf{E}}^{\bullet}}{{\mathbf{E}}}\Big) \Big\{\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}}){\mathbf{S}}-(\eta_1+\eta_2+\kappa){\mathbf{E}}\Big\}\\ & + {\rho}_3\Big(1-\frac{{\mathbf{A}}^{\bullet}}{{\mathbf{A}}}\Big) \Big\{\eta_1{\mathbf{E}}-(\delta_1+\delta_2+\kappa){\mathbf{A}}\Big\}\\ & + {\rho}_4\Big(1-\frac{{\mathbf{C}}^{\bullet}}{{\mathbf{C}}}\Big) \Big\{\eta_2{\mathbf{E}}+\delta_1{\mathbf{A}}-(\phi+\zeta+\kappa-\kappa\beta_1){\mathbf{C}}\Big\}\\ & + {\rho}_5\Big(1-\frac{{\mathbf{T}}^{\bullet}}{{\mathbf{T}}}\Big) \Big\{\phi{\mathbf{C}}-(\chi+\kappa){\mathbf{T}}\Big\}. \end{split} \end{equation} (4.21)

    Let {\mathbf{S}} = {\mathbf{S}}-{\mathbf{S}}^{\bullet} , {\mathbf{E}} = {\mathbf{E}}-{\mathbf{E}}^{\bullet} , {\mathbf{A}} = {\mathbf{A}}-{\mathbf{A}}^{\bullet} , {\mathbf{C}} = {\mathbf{C}}-{\mathbf{C}}^{\bullet} , and {\mathbf{T}} = {\mathbf{T}}-{\mathbf{T}}^{\bullet} , then we have

    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{X}\; \leq\; & {\rho}_1\Big(1-\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}\Big) \Big\{\kappa-\kappa\beta_1({\mathbf{C}}-{\mathbf{C}}^{\bullet}) +(\kappa_2-\kappa\vartheta)\big(1-({\mathbf{S}}-{\mathbf{S}}^{\bullet})-({\mathbf{E}}-{\mathbf{E}}^{\bullet})-({\mathbf{A}}-{\mathbf{A}}^{\bullet}) \\ &-({\mathbf{C}}-{\mathbf{C}}^{\bullet})-({\mathbf{T}}-{\mathbf{T}}^{\bullet})\big)-\big[\eta\lambda(({\mathbf{A}}-{\mathbf{A}}^{\bullet})+\xi({\mathbf{C}}-{\mathbf{C}}^{\bullet})) +\kappa+\alpha\big]({\mathbf{S}}-{\mathbf{S}}^{\bullet}) \Big\} \\ &+ {\rho}_2\Big(1-\frac{{\mathbf{E}}^{\bullet}}{{\mathbf{E}}}\Big)\Big\{\eta\lambda(({\mathbf{A}}-{\mathbf{A}}^{\bullet})+\xi({\mathbf{C}}-{\mathbf{C}}^{\bullet}))({\mathbf{S}}-{\mathbf{S}}^{\bullet}) -(\eta_1+\eta_2+\kappa)({\mathbf{E}}-{\mathbf{E}}^{\bullet})\Big\} \\ &+ {\rho}_3\Big(1-\frac{{\mathbf{A}}^{\bullet}}{{\mathbf{A}}}\Big)\Big\{\eta_1({\mathbf{E}}-{\mathbf{E}}^{\bullet}) -(\delta_1+\delta_2+\kappa)({\mathbf{A}}-{\mathbf{A}}^{\bullet})\Big\} \\ &+{\rho}_4\Big(1-\frac{{\mathbf{C}}^{\bullet}}{{\mathbf{C}}}\Big)\Big\{\eta_2({\mathbf{E}}-{\mathbf{E}}^{\bullet}) +\delta_1({\mathbf{A}}-{\mathbf{A}}^{\bullet})-(\phi+\zeta+\kappa-\kappa\beta_1)({\mathbf{C}}-{\mathbf{C}}^{\bullet})\Big\}\\ &+{\rho}_5\Big(1-\frac{{\mathbf{T}}^{\bullet}}{{\mathbf{T}}}\Big)\Big\{\phi({\mathbf{C}}-{\mathbf{C}}^{\bullet}) -(\chi+\kappa)({\mathbf{T}}-{\mathbf{T}}^{\bullet})\Big\}. \end{split} \end{equation} (4.22)
    \begin{equation} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{X} \leq \begin{cases} {\rho}_1\kappa-{\rho}_1\kappa\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}-{\rho}_1\kappa\beta_1({\mathbf{C}}-{\mathbf{C}}^{\bullet}) +{\rho}_1\kappa\beta_1\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}({\mathbf{C}}-{\mathbf{C}}^{\bullet}) +{\rho}_1(\kappa_2-\kappa\vartheta)-{\rho}_1\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}} (\kappa_2-\kappa\vartheta)\\ -{\rho}_1(\kappa_2-\kappa\vartheta)\frac{({\mathbf{S}}-{\mathbf{S}}^{\bullet})^2}{{\mathbf{S}}}-{\rho}_1(\kappa_2-\kappa\vartheta)({\mathbf{E}}-{\mathbf{E}}^{\bullet})+ {\rho}_1(\kappa_2-\kappa\vartheta)\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}({\mathbf{E}}-{\mathbf{E}}^{\bullet})\\ -{\rho}_1(\kappa_2-\kappa\vartheta)({\mathbf{A}}-{\mathbf{A}}^{\bullet})+ {\rho}_1(\kappa_2-\kappa\vartheta)\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}({\mathbf{A}}-{\mathbf{A}}^{\bullet}) -{\rho}_1(\kappa_2-\kappa\vartheta)({\mathbf{C}}-{\mathbf{C}}^{\bullet})\\ + {\rho}_1(\kappa_2-\kappa\vartheta)\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}({\mathbf{C}}-{\mathbf{C}}^{\bullet}) -{\rho}_1(\kappa_2-\kappa\vartheta)({\mathbf{T}}-{\mathbf{T}}^{\bullet})+ {\rho}_1(\kappa_2-\kappa\vartheta)\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}({\mathbf{T}}-{\mathbf{T}}^{\bullet})\\ -{\rho}_1\big[\eta\lambda(({\mathbf{A}}-{\mathbf{A}}^{\bullet})+\xi({\mathbf{C}}-{\mathbf{C}}^{\bullet})) +\kappa+\alpha\big]\frac{({\mathbf{S}}-{\mathbf{S}}^{\bullet})^2}{{\mathbf{S}}}+{\rho}_2\eta\lambda({\mathbf{A}}-{\mathbf{A}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet})\\ -{\rho}_2\eta\lambda\frac{{\mathbf{E}}^{\bullet}}{{\mathbf{E}}}({\mathbf{A}}-{\mathbf{A}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet}) +{\rho}_2\eta\lambda\xi({\mathbf{C}}-{\mathbf{C}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet})-{\rho}_2\eta\lambda\xi\frac{{\mathbf{E}}^{\bullet}}{{\mathbf{E}}}({\mathbf{C}}-{\mathbf{C}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet})\\ - {\rho}_2 (\eta_1+\eta_2+\kappa)\frac{({\mathbf{E}}-{\mathbf{E}}^{\bullet})^2}{{\mathbf{E}}}+{\rho}_3\eta_1({\mathbf{E}}-{\mathbf{E}}^{\bullet}) -{\rho}_3\eta_1\frac{{\mathbf{A}}^{\bullet}}{{\mathbf{A}}}({\mathbf{E}}-{\mathbf{E}}^{\bullet})\\-{\rho}_3(\delta_1+\delta_2+\kappa)\frac{({\mathbf{A}}-{\mathbf{A}}^{\bullet})^2}{{\mathbf{A}}} +{\rho}_4\eta_2({\mathbf{E}}-{\mathbf{E}}^{\bullet})-{\rho}_4\eta_2\frac{{\mathbf{C}}^{\bullet}}{{\mathbf{C}}}({\mathbf{E}}-{\mathbf{E}}^{\bullet})\\ +{\rho}_4\delta_1({\mathbf{A}}-{\mathbf{A}}^{\bullet})-{\rho}_4\delta_1\frac{{\mathbf{C}}^{\bullet}}{{\mathbf{C}}}({\mathbf{A}}-{\mathbf{A}}^{\bullet})-{\rho}_4(\phi+\zeta+\kappa-\kappa\beta_1) \frac{({\mathbf{C}}-{\mathbf{C}}^{\bullet})^2}{{\mathbf{C}}}+{\rho}_5\phi({\mathbf{C}}-{\mathbf{C}}^{\bullet})\\ -{\rho}_5\phi\frac{{\mathbf{T}}^{\bullet}}{{\mathbf{T}}}({\mathbf{C}}-{\mathbf{C}}^{\bullet})-{\rho}_5(\chi+\kappa)\frac{({\mathbf{T}}-{\mathbf{T}}^{\bullet})^2}{{\mathbf{T}}}. \end{cases} \end{equation} (4.23)

    Let {\rho}_1 = {\rho}_2 = {\rho}_3 = {\rho}_4 = {\rho}_5 = 1 and after simplifying above, we can express

    \begin{equation} {}_{j}^{mabc}\nabla^{\sigma}\mathcal{X} \; \leq \; A-B \; , \end{equation} (4.24)

    where

    \begin{equation*} \begin{split} A = &\kappa +\kappa\beta_1\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}({\mathbf{C}}-{\mathbf{C}}^{\bullet})+(\kappa_2-\kappa\vartheta)+(\kappa_2-\kappa\vartheta) \frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}\big[ ({\mathbf{E}}-{\mathbf{E}}^{\bullet})+({\mathbf{A}}-{\mathbf{A}}^{\bullet})+ ({\mathbf{C}}-{\mathbf{C}}^{\bullet}) + ({\mathbf{T}}-{\mathbf{T}}^{\bullet})\big]\\ &+\eta\lambda({\mathbf{A}}-{\mathbf{A}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet})+\eta\lambda\xi({\mathbf{C}}-{\mathbf{C}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet})+(\eta_1+\eta_2)({\mathbf{E}}-{\mathbf{E}}^{\bullet})+\delta_1({\mathbf{A}}-{\mathbf{A}}^{\bullet})+\phi({\mathbf{C}}-{\mathbf{C}}^{\bullet}). \end{split} \end{equation*}
    \begin{equation*} \begin{split} B = &\kappa\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}}+\kappa\beta_1({\mathbf{C}}-{\mathbf{C}}^{\bullet})+(\kappa_2-\kappa\vartheta)\Big[\frac{{\mathbf{S}}^{\bullet}}{{\mathbf{S}}} +\frac{({\mathbf{S}}-{\mathbf{S}}^{\bullet})^2}{{\mathbf{S}}}+({\mathbf{E}}-{\mathbf{E}}^{\bullet})+({\mathbf{A}}-{\mathbf{A}}^{\bullet}) +({\mathbf{C}}-{\mathbf{C}}^{\bullet}) +({\mathbf{T}}-{\mathbf{T}}^{\bullet})\Big]\\ &+\big[\eta\lambda(({\mathbf{A}}-{\mathbf{A}}^{\bullet})+\xi({\mathbf{C}}-{\mathbf{C}}^{\bullet})) +\kappa+\alpha\big]\frac{({\mathbf{S}}-{\mathbf{S}}^{\bullet})^2}{{\mathbf{S}}} +\eta\lambda\frac{{\mathbf{E}}^{\bullet}}{{\mathbf{E}}}({\mathbf{A}}-{\mathbf{A}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet})+\eta\lambda\xi\frac{{\mathbf{E}}^{\bullet}}{{\mathbf{E}}}({\mathbf{C}}-{\mathbf{C}}^{\bullet})({\mathbf{S}}-{\mathbf{S}}^{\bullet})\\ &+ (\eta_1+\eta_2+\kappa)\frac{({\mathbf{E}}-{\mathbf{E}}^{\bullet})^2}{{\mathbf{E}}} +\eta_1\frac{{\mathbf{A}}^{\bullet}}{{\mathbf{A}}}({\mathbf{E}}-{\mathbf{E}}^{\bullet})+(\delta_1+\delta_2+\kappa)\frac{({\mathbf{A}}-{\mathbf{A}}^{\bullet})^2}{{\mathbf{A}}} +\eta_2\frac{{\mathbf{C}}^{\bullet}}{{\mathbf{C}}}({\mathbf{E}}-{\mathbf{E}}^{\bullet})\\ &+\delta_1\frac{{\mathbf{C}}^{\bullet}}{{\mathbf{C}}}({\mathbf{A}}-{\mathbf{A}}^{\bullet})+(\phi+\zeta+\kappa-\kappa\beta_1) \frac{({\mathbf{C}}-{\mathbf{C}}^{\bullet})^2}{{\mathbf{C}}} +\phi\frac{{\mathbf{T}}^{\bullet}}{{\mathbf{T}}}({\mathbf{C}}-{\mathbf{C}}^{\bullet})+(\chi+\kappa)\frac{({\mathbf{T}}-{\mathbf{T}}^{\bullet})^2}{{\mathbf{T}}}. \end{split} \end{equation*}

    We notice that for \mathscr{R}_0 > 1

    A < B\; \; \; \; \; \; \; \; \Rightarrow\; \; \; \; {}_{j}^{mabc}\nabla^{\sigma}\mathcal{X}\leq 0,

    and when we let {\mathbf{S}} = {\mathbf{S}}^{\bullet} , {\mathbf{E}} = {\mathbf{E}}^{\bullet} , {\mathbf{A}} = {\mathbf{A}}^{\bullet} , {\mathbf{C}} = {\mathbf{C}}^{\bullet} , and {\mathbf{T}} = {\mathbf{T}}^{\bullet} , then

    A-B = 0\; \; \; \; \; \; \; \; \Rightarrow\; \; \; \; {}_{j}^{mabc}\nabla^{\sigma}\mathcal{X} = 0.

    The system (4.10) is therefore determined to be globally asymptotically stable.

    The presence and uniqueness of the solution are demonstrated in this part by illustrating that the underlying coefficients of the proposed system fulfill the Lipschitz and linear growth requirements.

    Consider \mathfrak{Q} = (\mathfrak{Q}_1, \mathfrak{Q}_2, \mathfrak{Q}_3, \mathfrak{Q}_4, \mathfrak{Q}_5, \mathfrak{Q}_6) such that

    \begin{align} \mathfrak{Q}_{1}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}) = & \kappa-\kappa\beta_1{\mathbf{C}}-\kappa\vartheta{\mathbf{R}}+\kappa_2{\mathbf{R}}-\big[\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}})+\kappa+\alpha\big]{\mathbf{S}} ,\\ \mathfrak{Q}_{2}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}) = & \eta\lambda({\mathbf{A}}+\xi{\mathbf{C}}){\mathbf{S}}-(\eta_1+\eta_2+\kappa){\mathbf{E}} ,\\ \mathfrak{Q}_{3}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}) = & \eta_1{\mathbf{E}}-(\delta_1+\delta_2+\kappa){\mathbf{A}},\\ \mathfrak{Q}_{4}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}) = & \eta_2{\mathbf{E}}+\delta_1{\mathbf{A}}-(\phi+\zeta+\kappa-\kappa\beta_1){\mathbf{C}} ,\\ \mathfrak{Q}_{5}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}) = & \phi{\mathbf{C}}-(\chi+\kappa){\mathbf{T}},\\ \mathfrak{Q}_{6}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}) = & \chi{\mathbf{T}}+\delta_2{\mathbf{A}}+\alpha{\mathbf{S}}+(\kappa\vartheta-\kappa-\kappa_2){\mathbf{R}}. \end{align} (4.25)

    Let \mathsf{G} = ({\mathbf{S}}, {\mathbf{E}}, {\mathbf{A}}, {\mathbf{C}}, {\mathbf{T}}, {\mathbf{R}})\in \mathcal{W} , where \mathcal{W} = [\mathrm{C}([0, \mathbb{T}], \mathbb{R}_{+})]^6 is a Banach space built with the norm:

    \begin{equation} \|\mathsf{G}\| = \sup\limits_{t\in [0,\mathbb{T}]} \Big[|{\mathbf{S}}(t)|+|{\mathbf{E}}(t)|+|{\mathbf{A}}(t)|+|{\mathbf{C}}(t)|+|{\mathbf{T}}(t)+|{\mathbf{R}}(t)|\Big],\nonumber \end{equation}

    It is evident that \mathfrak{Q}\in[0, \mathbb{T}]\times \mathcal{W}]^6 is continuous. Also

    \begin{eqnarray} \mathsf{G}(t) = \begin{cases} {\mathbf{S}}(t)\\ {\mathbf{E}}(t)\\ {\mathbf{A}}(t)\\ {\mathbf{C}}(t)\\ {\mathbf{T}}(t)\\ {\mathbf{R}}(t) \nonumber \end{cases} \mathsf{G}_{0}(t) = \begin{cases} {\mathbf{S}}_0\\ {\mathbf{E}}_0\\ {\mathbf{A}}_0\\ {\mathbf{C}}_0\\ {\mathbf{T}}_0\\ {\mathbf{R}}_0 \end{cases} = \begin{cases} \mathfrak{Q}_{1}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ \mathfrak{Q}_{2}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ \mathfrak{Q}_{3}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ \mathfrak{Q}_{4}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ \mathfrak{Q}_{5}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ \mathfrak{Q}_{6}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}). \end{cases} \end{eqnarray}

    To prove the existence and originality of the solution, we must verify the subsequent theorem.

    Theorem 4.4. Suppose that there exist positive constants, \mathfrak{P}_{i} , \mho_{i} , (i = 1, 2, 3, 4, 5, 6) such that

    |\mathfrak{Q}_{i}(\mathsf{G}, t)|^{2} \leq \mathfrak{P}_{i}(1+|\mathsf{G}|^2) \ \ \ \, \ \ \ \ \ \forall (\mathsf{G}, t)\in \mathbb{R}^{6}\times [0, \mathbb{T}].

    |\mathfrak{Q}_{i}(\mathsf{G}_1, t)-\mathfrak{Q}_{i}(\mathsf{G}_2, t)|^2 \leq \mho_{i}|\mathsf{G}_1-\mathsf{G}_2|^2.

    Proof. With linear growth, we start.

    \begin{equation*} \begin{split} |\mathfrak{Q}_{1}(t,{\mathbf{S}},{\mathbf{E}},&{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} = \Big|\kappa-\kappa\beta_1{\mathbf{C}}-\kappa\vartheta{\mathbf{R}}+\kappa_2{\mathbf{R}}-\big[\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}})+\kappa+\alpha\big] {\mathbf{S}}\Big|^2\\ & \leq 2\{\kappa^2+\kappa^2\beta_1^2|{\mathbf{C}}|^2+(\kappa^2\vartheta^2+\kappa_2^2)|{\mathbf{R}}|\}+2\big|\big[\eta\lambda(|{\mathbf{A}}|+\xi|{\mathbf{C}}|)+\kappa+\alpha\big]\big|^2|{\mathbf{S}}|^2\\ & \leq 2\{\kappa^2+\kappa^2\beta_1^2\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{C}}|^2+(\kappa^2\vartheta^2+\kappa_2^2)\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{R}}|\}\\ &\; \; \; \; \; \; \; \; \; +2\big|\big[\eta\lambda(\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{A}}|+\xi\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{C}}|)+\kappa+\alpha\big]\big|^2|\sup\limits_{t\in[0,\mathbb{T}]}{\mathbf{S}}|^2\\ & \leq 2\{\kappa^2+\kappa^2\beta_1^2|{\mathbf{C}}|_{\infty}^2+(\kappa^2\vartheta^2+\kappa_2^2)|{\mathbf{R}}|_{\infty}\}+2\big|\big[\eta\lambda(|{\mathbf{A}}|_{\infty}+\xi|{\mathbf{C}}|_{\infty}) +\kappa+\alpha\big]\big|^2|{\mathbf{S}}|_{\infty}^2\\ & \leq 2\{\kappa^2+\kappa^2\beta_1^2|{\mathbf{C}}|_{\infty}^2+(\kappa^2\vartheta^2+\kappa_2^2)|{\mathbf{R}}|_{\infty}\} \Big[1+\frac{\big[\eta\lambda(|{\mathbf{A}}|_{\infty}+\xi|{\mathbf{C}}|_{\infty}) +\kappa+\alpha\big]^2}{\kappa^2+\kappa^2\beta_1^2|{\mathbf{C}}|_{\infty}^2+(\kappa^2\vartheta^2+\kappa_2^2)|{\mathbf{R}}|_{\infty}}|{\mathbf{S}}|_{\infty}^2\Big], \end{split} \end{equation*}
    \begin{equation} \Rightarrow \; \; |\mathfrak{Q}_{1}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} \leq\mathfrak{P}_{1}(1+|{\mathbf{S}}|_{\infty}^{2}),\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \frac{\big[\eta\lambda(|{\mathbf{A}}|_{\infty}+\xi|{\mathbf{C}}|_{\infty}) +\kappa+\alpha\big]^2}{\kappa^2+\kappa^2\beta_1^2|{\mathbf{C}}|_{\infty}^2+(\kappa^2\vartheta^2+\kappa_2^2)|{\mathbf{R}}|_{\infty}} < 1. \end{equation} (4.26)
    \begin{equation*} \begin{split} |\mathfrak{Q}_{2}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2}& = \Big|\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}}){\mathbf{S}}-(\eta_1+\eta_2+\kappa){\mathbf{E}}\Big|^2\\ & \leq 2\eta^2\lambda^2(|{\mathbf{A}}|^2+\xi^2|{\mathbf{C}}|^2)|{\mathbf{S}}|^2+2(\eta_1+\eta_2+\kappa)^2|{\mathbf{E}}|^2\\ & \leq 2\eta^2\lambda^2(\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{A}}|^2+\xi^2\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{C}}|^2)\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{S}}|^2+2(\eta_1+\eta_2+\kappa)^2\sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{E}}|^2\\ & \leq 2\eta^2\lambda^2(|{\mathbf{A}}|_{\infty}^2+\xi^2|{\mathbf{C}}|_{\infty}^2)|{\mathbf{S}}|_{\infty}^2+2(\eta_1+\eta_2+\kappa)^2|{\mathbf{E}}|_{\infty}^2\\ & \leq 2\eta^2\lambda^2(|{\mathbf{A}}|_{\infty}^2+\xi^2|{\mathbf{C}}|_{\infty}^2)|{\mathbf{S}}|_{\infty}^2\Big[1+\frac{(\eta_1+\eta_2+\kappa)^2}{\eta^2\lambda^2(|{\mathbf{A}}|_{\infty}^2 +\xi^2|{\mathbf{C}}|_{\infty}^2)|{\mathbf{S}}|_{\infty}^2}|{\mathbf{E}}|_{\infty}^2\Big], \end{split} \end{equation*}
    \begin{equation} \Rightarrow \; \; |\mathfrak{Q}_{2}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} \leq\mathfrak{P}_{2}(1+|{\mathbf{E}}|_{\infty}^{2}),\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \frac{(\eta_1+\eta_2+\kappa)^2}{\eta^2\lambda^2(|{\mathbf{A}}|_{\infty}^2 +\xi^2|{\mathbf{C}}|_{\infty}^2)} < 1. \end{equation} (4.27)
    \begin{equation*} \begin{split} |\mathfrak{Q}_{3}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2}& = \Big|\eta_1{\mathbf{E}}-(\delta_1+\delta_2+\kappa){\mathbf{A}}\Big|^2 \; \; \leq \; \; 2\eta_1^2|{\mathbf{E}}|^2+2(\delta_1+\delta_2+\kappa)^2|{\mathbf{A}}|^2\\ & \leq 2\eta_1^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{E}}|^2+2(\delta_1+\delta_2+\kappa)^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{A}}|^2\\ & \leq 2\eta_1^2|{\mathbf{E}}|_{\infty}^2+2(\delta_1+\delta_2+\kappa)^2|{\mathbf{A}}|_{\infty}^2 \; \; \leq \; \; 2\eta_1^2|{\mathbf{E}}|_{\infty}^2\Big[1+\frac{(\delta_1+\delta_2+\kappa)^2}{\eta_1^2|{\mathbf{E}}|_{\infty}^2}|{\mathbf{A}}|_{\infty}^2\Big],\\ \end{split} \end{equation*}
    \begin{equation} \Rightarrow \; \; |\mathfrak{Q}_{3}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} \leq\mathfrak{P}_{3}(1+|{\mathbf{A}}|_{\infty}^{2}), \; \; \; \; \; \; \; \; \; \; \; \; \; \; \frac{(\delta_1+\delta_2+\kappa)^2}{\eta_1^2|{\mathbf{E}}|_{\infty}^2} < 1. \end{equation} (4.28)
    \begin{equation*} \begin{split} |\mathfrak{Q}_{4}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2}& = \Big|\eta_2{\mathbf{E}}+\delta_1{\mathbf{A}}-(\phi+\zeta+\kappa-\kappa\beta_1){\mathbf{C}}\Big|^2\\ & \leq 2(\eta_2^2|{\mathbf{E}}|^2+\delta_1^2|{\mathbf{A}}|^2)+2(\phi+\zeta+\kappa-\kappa\beta_1)^2|{\mathbf{C}}|^2\\ & \leq 2(\eta_2^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{E}}|^2+\delta_1^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{A}}|^2)+2(\phi+\zeta+\kappa-\kappa\beta_1)^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{C}}|^2\\ & \leq 2(\eta_2^2|{\mathbf{E}}|_{\infty}^2+\delta_1^2|{\mathbf{A}}|_{\infty}^2)+2(\phi+\zeta+\kappa-\kappa\beta_1)^2|{\mathbf{C}}|_{\infty}^2\\ & \leq 2(\eta_2^2|{\mathbf{E}}|_{\infty}^2+\delta_1^2|{\mathbf{A}}|_{\infty}^2)\Big[1+\frac{(\phi+\zeta+\kappa-\kappa\beta_1)^2}{\eta_2^2|{\mathbf{E}}|_{\infty}^2 +\delta_1^2|{\mathbf{A}}|_{\infty}^2}|{\mathbf{E}}|_{\infty}^2\Big], \end{split} \end{equation*}
    \begin{equation} \Rightarrow \; \; |\mathfrak{Q}_{4}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} \leq\mathfrak{P}_{4}(1+|{\mathbf{C}}|_{\infty}^{2}),\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \frac{(\phi+\zeta+\kappa-\kappa\beta_1)^2}{\eta_2^2|{\mathbf{E}}|_{\infty}^2 +\delta_1^2|{\mathbf{A}}|_{\infty}^2} < 1. \end{equation} (4.29)
    \begin{equation*} \begin{split} |\mathfrak{Q}_{5}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2}& = \Big|\phi{\mathbf{C}}-(\chi+\kappa){\mathbf{T}}\Big|^2 \; \; \leq \; \; 2\phi^2|{\mathbf{C}}|^2+2(\chi+\kappa)^2|{\mathbf{T}}|^2\\ & \leq 2\phi^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{C}}|^2+2(\chi+\kappa)^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{T}}|^2\\ & \leq 2\phi^2|{\mathbf{C}}|_{\infty}^2+2(\chi+\kappa)^2|{\mathbf{T}}|_{\infty}^2 \; \; \leq \; \; 2\phi^2|{\mathbf{C}}|_{\infty}^2\Big[1+\frac{(\chi+\kappa)^2}{\phi^2|{\mathbf{C}}|_{\infty}^2}|{\mathbf{T}}|_{\infty}^2\Big],\\ \end{split} \end{equation*}
    \begin{equation} \Rightarrow \; \; |\mathfrak{Q}_{5}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} \leq\mathfrak{P}_{5}(1+|{\mathbf{T}}|_{\infty}^{2}), \; \; \; \; \; \; \; \; \; \; \; \; \; \; \frac{(\chi+\kappa)^2}{\phi^2|{\mathbf{C}}|_{\infty}^2} < 1. \end{equation} (4.30)
    \begin{equation*} \begin{split} |\mathfrak{Q}_{6}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2}& = \Big|\chi{\mathbf{T}}+\delta_2{\mathbf{A}}+\alpha{\mathbf{S}}+(\kappa\vartheta-\kappa-\kappa_2) {\mathbf{R}}\Big|^2\\ & \leq 2(\chi_2^2|{\mathbf{T}}|^2+\delta_2^2|{\mathbf{A}}|^2+\alpha^2|{\mathbf{S}}|^2)+2(\kappa\vartheta-\kappa-\kappa_2)^2|{\mathbf{R}}|^2\\ & \leq 2(\chi_2^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{T}}|^2+\delta_2^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{A}}|^2+\alpha^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{S}}|^2) +2(\kappa\vartheta-\kappa-\kappa_2)^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{R}}|^2\\ & \leq 2(\chi_2^2|{\mathbf{T}}|_{\infty}^2+\delta_2^2|{\mathbf{A}}|_{\infty}^2+\alpha^2|{\mathbf{S}}|_{\infty}^2)+2(\kappa\vartheta-\kappa-\kappa_2)^2|{\mathbf{R}}|_{\infty}^2\\ & \leq 2(\chi_2^2|{\mathbf{T}}|_{\infty}^2+\delta_2^2|{\mathbf{A}}|_{\infty}^2+\alpha^2|{\mathbf{S}}|_{\infty}^2)\Big[1+\frac{(\kappa\vartheta-\kappa-\kappa_2)^2}{(\chi_2^2|{\mathbf{T}}|_{\infty}^2 +\delta_2^2|{\mathbf{A}}|_{\infty}^2+\alpha^2|{\mathbf{S}}|_{\infty}^2)}|{\mathbf{R}}|_{\infty}^2\Big], \end{split} \end{equation*}
    \begin{equation} \Rightarrow \; \; |\mathfrak{Q}_{6}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} \leq\mathfrak{P}_{6}(1+|{\mathbf{R}}|_{\infty}^{2}),\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \frac{(\phi+\zeta+\kappa-\kappa\beta_1)^2}{\eta_2^2|{\mathbf{E}}|_{\infty}^2 +\delta_1^2|{\mathbf{A}}|_{\infty}^2} < 1. \end{equation} (4.31)

    Thus, the function satisfies the criteria for growth. We'll now assess the Lipschitz scenario. We have

    \begin{equation*} \begin{split} |\mathfrak{Q}_{1}(t,{\mathbf{S}}_1,{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})&-\mathfrak{Q}_{1}(t,{\mathbf{S}}_2,{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2}\\ & = \big|\big[\eta\lambda({\mathbf{A}}+\xi{\mathbf{C}})+\kappa+\alpha\big]({\mathbf{S}}_{1}-{\mathbf{S}}_{2})\big|^{2}\\ & \leq \Big(2\eta^2\lambda^2|{\mathbf{A}}|^2+2\eta^2\lambda^2\xi^2|{\mathbf{C}}|^2+2\kappa^2+2\alpha^2\Big)\big|({\mathbf{S}}_{1}-{\mathbf{S}}_{2})\big|^{2}\\ & \leq \Big(2\eta^2\lambda^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{A}}|^2+2\eta^2\lambda^2\xi^2 \sup\limits_{t\in[0,\mathbb{T}]}|{\mathbf{C}}|^2+2\kappa^2+2\alpha^2\Big)\big|({\mathbf{S}}_{1}-{\mathbf{S}}_{2})\big|^{2}\\ & = \Big(2\eta^2\lambda^2|{\mathbf{A}}|_{\infty}^2+2\eta^2\lambda^2\xi^2|{\mathbf{C}}|_{\infty}^2+2\kappa^2+2\alpha^2\Big)\big|({\mathbf{S}}_{1}-{\mathbf{S}}_{2})\big|^{2}\\ & \leq \mho_{1}|{\mathbf{S}}_{1}-{\mathbf{S}}_{2}|^{2}. \end{split} \end{equation*}
    \begin{equation} \begin{split} |\mathfrak{Q}_{2}(t,{\mathbf{S}},{\mathbf{E}}_1,{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})-\mathfrak{Q}_{2}(t,{\mathbf{S}},{\mathbf{E}}_2,{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} & = \big|(\eta_1+\eta_2+\kappa)({\mathbf{E}}_{1}-{\mathbf{E}}_{2})\big|^{2}\\ & \leq \Big(2\eta_1^2+2\eta_2^2+2\kappa^2\Big)\big|({\mathbf{E}}_{1}-{\mathbf{E}}_{2})\big|^{2}\\ & \leq \mho_{2}|{\mathbf{E}}_{1}-{\mathbf{E}}_{2}|^{2}. \end{split} \end{equation} (4.32)
    \begin{equation} \begin{split} |\mathfrak{Q}_{3}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}}_1,{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})-\mathfrak{Q}_{3}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}}_2,{\mathbf{C}},{\mathbf{T}},{\mathbf{R}})|^{2} & = \big|(\delta_1+\delta_2+\kappa)({\mathbf{A}}_{1}-{\mathbf{A}}_{2})\big|^{2}\\ & \leq \Big(2\delta_1^2+2\delta_2^2+2\kappa^2\Big)\big|({\mathbf{A}}_{1}-{\mathbf{A}}_{2})\big|^{2}\\ & \leq \mho_{3}|{\mathbf{A}}_{1}-{\mathbf{A}}_{2}|^{2}. \end{split} \end{equation} (4.33)
    \begin{equation} \begin{split} |\mathfrak{Q}_{4}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}}_1,{\mathbf{T}},{\mathbf{R}})-\mathfrak{Q}_{4}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}}_2,{\mathbf{T}},{\mathbf{R}})|^{2} & = \big|(\phi+\zeta+\kappa-\kappa\beta_1)({\mathbf{C}}_{1}-{\mathbf{C}}_{2})\big|^{2}\\ & \leq \Big(2\phi^2+2\zeta^2+2\kappa^2+2\kappa^2\beta_1^2\Big)\big|({\mathbf{C}}_{1}-{\mathbf{C}}_{2})\big|^{2}\\ & \leq \mho_{4}|{\mathbf{C}}_{1}-{\mathbf{C}}_{2}|^{2}. \end{split} \end{equation} (4.34)
    \begin{equation} \begin{split} |\mathfrak{Q}_{5}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}}_1,{\mathbf{R}})-\mathfrak{Q}_{5}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}}_2,{\mathbf{R}})|^{2} & = \big|(\chi+\kappa)({\mathbf{T}}_{1}-{\mathbf{T}}_{2})\big|^{2}\\ & \leq \Big(2\chi^2+2\kappa^2\Big)\big|({\mathbf{T}}_{1}-{\mathbf{T}}_{2})\big|^{2}\\ & \leq \mho_{5}|{\mathbf{T}}_{1}-{\mathbf{T}}_{2}|^{2}. \end{split} \end{equation} (4.35)
    \begin{equation} \begin{split} |\mathfrak{Q}_{6}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}_1)-\mathfrak{Q}_{6}(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}_2)|^{2} & = \big|(\kappa\vartheta-\kappa-\kappa_2)({\mathbf{R}}_{1}-{\mathbf{R}}_{2})\big|^{2}\\ & \leq \Big(2\kappa\vartheta^2+2\kappa^2+2\kappa_2^2\Big)\big|({\mathbf{R}}_{1}-{\mathbf{R}}_{2})\big|^{2}\\ & \leq \mho_{6}|{\mathbf{R}}_{1}-{\mathbf{R}}_{2}|^{2}. \end{split} \end{equation} (4.36)

    Here

    \begin{eqnarray} \mho_1 & = & 2\eta^2\lambda^2|{\mathbf{A}}|_{\infty}^2+2\eta^2\lambda^2\xi^2|{\mathbf{C}}|_{\infty}^2+2\kappa^2+2\alpha^2, \\ \mho_2 & = & 2\eta_1^2+2\eta_2^2+2\kappa^2, \\ \mho_3 & = & 2\delta_1^2+2\delta_2^2+2\kappa^2, \\ \mho_4 & = & 2\phi^2+2\zeta^2+2\kappa^2+2\kappa^2\beta_1^2, \\ \mho_5 & = & 2\chi^2+2\kappa^2, \\ \mho_6 & = & 2\kappa\vartheta^2+2\kappa^2+2\kappa_2^2. \end{eqnarray} (4.37)

    The solution to our system (3.1) therefore exists and is particularly given the specific conditions.

    \begin{equation} \max \begin{cases} \big\{\frac{\big[\eta\lambda(|{\mathbf{A}}|_{\infty}+\xi|{\mathbf{C}}|_{\infty}) +\kappa+\alpha\big]^2}{\kappa^2+\kappa^2\beta_1^2|{\mathbf{C}}|_{\infty}^2+(\kappa^2\vartheta^2+\kappa_2^2)|{\mathbf{R}}|_{\infty}}\big\},\\ \big\{\frac{(\eta_1+\eta_2+\kappa)^2}{\eta^2\lambda^2(|{\mathbf{A}}|_{\infty}^2 +\xi^2|{\mathbf{C}}|_{\infty}^2)|{\mathbf{S}}|_{\infty}^2}\big\},\\ \big\{\frac{(\delta_1+\delta_2+\kappa)^2}{\eta_1^2|{\mathbf{E}}|_{\infty}^2}\big\},\\ \big\{\frac{(\phi+\zeta+\kappa-\kappa\beta_1)^2}{\eta_2^2|{\mathbf{E}}|_{\infty}^2 +\delta_1^2|{\mathbf{A}}|_{\infty}^2}\big\},\\ \big\{\frac{(\chi+\kappa)^2}{\phi^2|{\mathbf{C}}|_{\infty}^2}\big\},\\ \big\{\frac{(\phi+\zeta+\kappa-\kappa\beta_1)^2}{\eta_2^2|{\mathbf{E}}|_{\infty}^2 +\delta_1^2|{\mathbf{A}}|_{\infty}^2}\big\} \end{cases} < 1. \end{equation} (4.38)

    We implement \sigma -monotonicity study for the discrete nabla fractional operators in this part. First, as mentioned in [39], we review the definitions of \sigma -monotones for each 0 \in(0, 1] and a function \wp:\mathbb{N}_j\rightarrow \mathbb{R} fulfilling \wp(j) = 0 .

    \wp is referred to as a \sigma -monotone rising function on \mathbb{N}_j in the following case

    \begin{equation} \wp(h + 1) \geq \sigma\wp(h),\; \; \; \; \; \; \; \; \; \; \; \forall h\in\mathbb{N}_j. \end{equation} (5.1)

    \wp is referred to as a \sigma -monotone falling function on \mathbb{N}_j in the following case

    \begin{equation} \wp(h + 1) \leq \sigma\wp(h),\; \; \; \; \; \; \; \; \; \; \; \forall h\in\mathbb{N}_j. \end{equation} (5.2)

    ● On \mathbb{N}_j , the function \wp is referred to as a \sigma -monotone extremely rising function if

    \begin{equation} \wp(h + 1) > \sigma\wp(h),\; \; \; \; \; \; \; \; \; \; \; \forall h\in\mathbb{N}_j. \end{equation} (5.3)

    ● On \mathbb{N}_j , the function \wp is referred to as a \sigma -monotone extremely falling function if

    \begin{equation} \wp(h + 1) < \sigma\wp(h),\; \; \; \; \; \; \; \; \; \; \; \forall h\in\mathbb{N}_j. \end{equation} (5.4)

    Remark 5.1. It is evident that for \sigma\in(0, 1] , if \wp(h) is rising or falling on \mathbb{N}_j , then we have

    \begin{equation} \wp(h + 1) \geq \wp(h) \geq \sigma\wp(h) \; \; \; \; \; \; \; \; \; \; \; \forall h\in\mathbb{N}_j, \end{equation} (5.5)

    or

    \begin{equation} \wp(h + 1) \leq \wp(h) \leq \sigma\wp(h), \; \; \; \; \; \; \; \; \; \; \; \forall h\in\mathbb{N}_j. \end{equation} (5.6)

    This indicates that on \mathbb{N}_j , \wp(h) is either \sigma -monotone rising or falling.

    Theorem 5.1. Assume that \sigma\in(0, \frac{1}{2}) . When functions \{{\mathbf{S}}, {\mathbf{E}}, {\mathbf{A}}, {\mathbf{C}}, {\mathbf{T}}, {\mathbf{R}}\}:\mathbb{N}_j\rightarrow \mathbb{R} fulfill

    \begin{equation} \begin{split} {\mathbf{S}}(j) = 0\; \; \; \; \; \; \; \; \; \; and\; \; \; \; \; \; \; \; \; {}_j^{abc}\nabla^{\sigma}{\mathbf{S}}(t)\geq 0,\\ {\mathbf{E}}(j) = 0\; \; \; \; \; \; \; \; \; \; and\; \; \; \; \; \; \; \; \; {}_j^{abc}\nabla^{\sigma}{\mathbf{E}}(t)\geq 0,\\ {\mathbf{A}}(j) = 0\; \; \; \; \; \; \; \; \; \; and\; \; \; \; \; \; \; \; \; {}_j^{abc}\nabla^{\sigma}{\mathbf{A}}(t)\geq 0,\\ {\mathbf{C}}(j) = 0\; \; \; \; \; \; \; \; \; \; and\; \; \; \; \; \; \; \; \; {}_j^{abc}\nabla^{\sigma}{\mathbf{C}}(t)\geq 0,\\ {\mathbf{T}}(j) = 0\; \; \; \; \; \; \; \; \; \; and\; \; \; \; \; \; \; \; \; {}_j^{abc}\nabla^{\sigma}{\mathbf{T}}(t)\geq 0,\\ {\mathbf{R}}(j) = 0\; \; \; \; \; \; \; \; \; \; and\; \; \; \; \; \; \; \; \; {}_j^{abc}\nabla^{\sigma}{\mathbf{R}}(t)\geq 0,\\ \end{split} \end{equation} (5.7)

    \forall t\in\mathbb{N}_{j+1} , then {\mathbf{S}}(t), {\mathbf{E}}(t), {\mathbf{A}}(t), {\mathbf{C}}(t), {\mathbf{T}}(t), {\mathbf{R}}(t) > 0 . Moreover, on \mathbb{N}_j , {\mathbf{S}}, {\mathbf{E}}, {\mathbf{A}}, {\mathbf{C}}, {\mathbf{T}}, {\mathbf{R}} are \chi^2 -monotone rising functions.

    Proof. From Definition 2.7 and Remark 2.1, we have \forall t\in\mathbb{N}_j

    \begin{equation} \begin{cases} {}_j^{ab}\nabla^{\sigma}[{{\mathbf{S}}}(t)] = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}\nabla {{\mathbf{S}}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega),\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{E}}}(t)] = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}\nabla {{\mathbf{E}}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega),\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{A}}}(t)] = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}\nabla {{\mathbf{A}}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega),\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{C}}}(t)] = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}\nabla {{\mathbf{C}}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega),\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{T}}}(t)] = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}\nabla {{\mathbf{T}}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega),\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{R}}}(t)] = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}\nabla {{\mathbf{R}}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega). \end{cases} \end{equation} (5.8)

    Using function {\mathbf{S}} , we determine

    \begin{equation} {}_j^{mabc}\nabla^{\sigma}[{\mathrm{X}}(t)] = \frac{ab(\sigma)}{1-\sigma}\Big({\mathrm{X}}(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\mathrm{X}}(j) +\psi \sum\limits_{\omega = j+1}^{t}\mathrm{E}_{\overline{\sigma,\sigma}}(\psi,t+1-\omega) {\mathrm{X}}(\omega)\Big) \ \ \ , \ \ \forall t\in\mathbb{N}_j. \end{equation} (5.9)
    \begin{equation} \begin{split} {}_j^{ab}\nabla^{\sigma}[{{\mathbf{S}}}(t)]& = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}\nabla {{\mathbf{S}}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) = \frac{ab(\sigma)}{1-\sigma} \sum\limits_{\omega = j+1}^{t}[{\mathbf{S}}(\omega)-{\mathbf{S}}(\omega-1)]\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega),\\ & = \frac{ab(\sigma)}{1-\sigma}\Big\{ \sum\limits_{\omega = j+1}^{t}{\mathbf{S}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)- \sum\limits_{\omega = j+1}^{t} {\mathbf{S}}(\omega-1)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)\Big\},\\ & = \frac{ab(\sigma)}{1-\sigma}\Big\{\mathrm{E}_{\overline\sigma}(\psi,1){\mathbf{S}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)+ \sum\limits_{\omega = j+1}^{t-1} {\mathbf{S}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; - \sum\limits_{\omega = j+1}^{t-1} {\mathbf{S}}(\omega)\; \mathrm{E}_{\overline\sigma}(\psi,t-\omega)\Big\},\\ & = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{S}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)+ \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(\omega)\Big\}. \end{split} \end{equation} (5.10)

    With the knowledge we have \frac{ab(\sigma)}{1-\sigma} > 0 and {}_j^{ab}\nabla^{\sigma}[{{\mathbf{S}}}(t)]\geq 0 , we can write

    \begin{equation} {{\mathbf{S}}}(t) \geq \frac{1}{1-\sigma}\Big\{\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)+ \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)\big]{\mathbf{S}}(\omega)\Big\},\; \; \; \; \; \; \; \; t\in\mathbb{N}_{j+1}. \end{equation} (5.11)

    Strong induction is used to show that {\mathbf{S}}(t) > 0 for each t\in\mathbb{N}_{j} . Since {\mathbf{S}}(j) > 0 is the underlying assumption, if we further assume that {\mathbf{S}}(t) > 0 for each t\in\mathbb{N}_{j}^{\omega} = \{j, j + 1, ..., \omega\} , then for some \omega\in\mathbb{N}_{j} , we can deduce from Eq (5.11) that

    \begin{equation} {{\mathbf{S}}}(\omega+1) \geq \frac{1}{1-\sigma}\Big\{\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)+ \sum\limits_{\omega = j+1}^{\omega} \big[\underbrace{\mathrm{E}_{\overline\sigma}(\psi,t-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)}_{ > 0}\big]\underbrace{{\mathbf{S}}(\omega)}_{ > 0}\Big\} > 0,\; \; \; \; \; \; \; \; t\in\mathbb{N}_{j+1}. \end{equation} (5.12)

    It follows from Remark 2.1 that

    \begin{equation} \mathrm{E}_{\overline\sigma}(\psi,t-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) > 0. \end{equation} (5.13)

    Therefore, as required, we draw the conclusion that {\mathbf{S}}(t) > 0 for t\in\mathbb{N}_{j} .

    We rewrite Eq (5.11) as follows in order to demonstrate the \chi^2 -monotonicity of {\mathbf{S}} :

    \begin{equation} \begin{split} {{\mathbf{S}}}(t)& \geq \frac{1}{1-\sigma}\Big\{\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)+\big[\mathrm{E}_{\overline\sigma}(\psi,1)-\mathrm{E}_{\overline\sigma}(\psi,2)\big] {\mathbf{S}}(t-1)\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-2} \big[\mathrm{E}_{\overline\sigma}(\psi,t-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)\big]{\mathbf{S}}(\omega)\Big\}\\ & = \frac{1}{1-\sigma}\Big\{\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)+\chi^2{\mathbf{S}}(t-1) + \sum\limits_{\omega = j+1}^{t-2} \big[\mathrm{E}_{\overline\sigma}(\psi,t-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)\big]{\mathbf{S}}(\omega)\Big\} \end{split} \end{equation} (5.14)

    for each t\in\mathbb{N}_{j+1} . For every t\in\mathbb{N}_{j} , it is demonstrated that {\mathbf{S}}(t) > 0 . Additionally, from Remark 2.1, we know that \mathrm{E}_{\overline\sigma}(\psi, t) is monotonically decreasing for every t = 0, 1, ... Consequently, Eq (5.14) indicates that

    \begin{equation} {\mathbf{S}}(t)\geq \chi^2{\mathbf{S}}(t-1),\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1}. \end{equation} (5.15)

    This proves \chi^2 -monotone increasing of {\mathbf{S}} on \mathbb{N}_j . Likewise, we can demonstrate it for {\mathbf{E}} , {\mathbf{A}} , {\mathbf{C}} , {\mathbf{T}} , and {\mathbf{R}} .

    Remark 5.2. We can infer that {\mathbf{S}}, {\mathbf{E}}, {\mathbf{A}}, {\mathbf{C}}, {\mathbf{T}}, {\mathbf{R}} are \chi^2 -monotone strictly increasing on \mathbb{N}_j by limiting the conditions in Theorem (5.1) and {\mathbf{S}}(j), {\mathbf{E}}(j), {\mathbf{A}}(j), {\mathbf{C}}(j), {\mathbf{T}}(j), {\mathbf{R}}(j) > 0 , {}_j^{abc}\nabla^{\sigma}{\mathbf{S}}(t) > 0 , {}_j^{abc}\nabla^{\sigma}{\mathbf{E}}(t) > 0 , {}_j^{abc}\nabla^{\sigma}{\mathbf{A}}(t) > 0 , {}_j^{abc}\nabla^{\sigma}{\mathbf{C}}(t) > 0 , {}_j^{abc}\nabla^{\sigma}{\mathbf{T}}(t) > 0 , and {}_j^{abc}\nabla^{\sigma}{\mathbf{R}}(t) > 0 for each t\in\mathbb{N}_{j+1} .

    Theorem 5.2. Let {\mathbf{S}}, {\mathbf{E}}, {\mathbf{A}}, {\mathbf{C}}, {\mathbf{T}}, {\mathbf{R}} be defined on \mathbb{N}_j and increasing on \mathbb{N}_{j+1} with {\mathbf{S}}(j) = {\mathbf{E}}(j) = {\mathbf{A}}(j) = {\mathbf{C}}(j) = {\mathbf{T}}(j) = {\mathbf{R}}(j) = 0 . For \sigma\in(0, \frac{1}{2}) , we thus have

    \begin{equation} \begin{cases} {}_j^{abc}\nabla^{\sigma}{\mathbf{S}}(t)\geq 0, \; \; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1},\\ {}_j^{abc}\nabla^{\sigma}{\mathbf{E}}(t)\geq 0, \; \; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1},\\ {}_j^{abc}\nabla^{\sigma}{\mathbf{A}}(t)\geq 0, \; \; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1},\\ {}_j^{abc}\nabla^{\sigma}{\mathbf{C}}(t)\geq 0, \; \; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1},\\ {}_j^{abc}\nabla^{\sigma}{\mathbf{T}}(t)\geq 0, \; \; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1},\\ {}_j^{abc}\nabla^{\sigma}{\mathbf{R}}(t)\geq 0, \; \; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1}. \end{cases} \end{equation} (5.16)

    Proof. Using Theorem 5.1, we have

    \begin{equation} \begin{cases} {}_j^{ab}\nabla^{\sigma}[{{\mathbf{S}}}(t)] = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{S}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j) + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(\omega)\Big\},\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{E}}}(t)] = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{E}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{E}}(j) + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{E}}(\omega)\Big\},\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{A}}}(t)] = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{A}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{A}}(j) + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{A}}(\omega)\Big\},\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{C}}}(t)] = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{C}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{C}}(j) + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{C}}(\omega)\Big\},\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{T}}}(t)] = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{T}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{T}}(j) + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{T}}(\omega)\Big\},\\ {}_j^{ab}\nabla^{\sigma}[{{\mathbf{R}}}(t)] = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{R}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{R}}(j) + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{R}}(\omega)\Big\}. \end{cases} \end{equation} (5.17)

    By applying Remark 2.1 and raising {\mathbf{S}} on \mathbb{N}_{j+1} , it is evident that

    \begin{equation} \begin{split} {}_j^{ab}\nabla^{\sigma}[{{\mathbf{S}}}(t)]& = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{S}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j) -\sigma^2(1-\sigma){\mathbf{S}}(t-1)\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-2} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega)-\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(\omega)\Big\}\\ & = \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{S}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j) -\sigma^2(1-\sigma){\mathbf{S}}(t-1)\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-2} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) -\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(t-1)\big)\Big\}\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-2} \underbrace{\big[\underbrace{\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) -\mathrm{E}_{\overline\sigma}(\psi,t-\omega)}_{ < 0}\big]\big(\underbrace{{\mathbf{S}}(\omega)-{\mathbf{S}}(t-1)}_{\leq 0}\big)}_{\geq 0}\Big\}. \end{split} \end{equation} (5.18)

    This yields

    \begin{equation} \begin{split} {}_j^{ab}\nabla^{\sigma}[{{\mathbf{S}}}(t)]& \geq \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{S}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j) \\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) -\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(t-1)\big)\Big\}. \end{split} \end{equation} (5.19)

    Given that {\mathbf{S}} increases on \mathbb{N}_{j+1} and {\mathbf{S}}(j) = 0 , we can infer

    \begin{equation} {\mathbf{S}}(t) \geq {\mathbf{S}}(t-1)\geq {\mathbf{S}}(j)\geq 0,\; \; \; \; \; \; \; \; \; \; \; \; \forall t\in\mathbb{N}_{j+1}. \end{equation} (5.20)

    This implies that

    \begin{equation} \begin{split} {}_j^{ab}\nabla^{\sigma}[{{\mathbf{S}}}(t)]& \geq \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{S}}(t)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j) -(1-\sigma){\mathbf{S}}(t-1)+(1-\sigma){\mathbf{S}}(t-1)\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) -\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(t-1)\big)\Big\}\\ & = \frac{ab(\sigma)}{1-\sigma}\Big\{\underbrace{\underbrace{(1-\sigma)}_{ > 0}\big(\underbrace{{\mathbf{S}}(t)-{\mathbf{S}}(t-1)}_{\geq 0}}_{\geq 0}\big)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j) +(1-\sigma){\mathbf{S}}(t-1)\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) -\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(t-1)\big)\Big\}\\ &\geq \frac{ab(\sigma)}{1-\sigma}\Big\{(1-\sigma){\mathbf{S}}(t-1)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)\\ &\; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; \; + \sum\limits_{\omega = j+1}^{t-1} \big[\mathrm{E}_{\overline\sigma}(\psi,t+1-\omega) -\mathrm{E}_{\overline\sigma}(\psi,t-\omega)\big]{\mathbf{S}}(t-1)\big)\Big\}\\ & = \frac{ab(\sigma)}{1-\sigma}\Big\{\mathrm{E}_{\overline\sigma}(\psi,1){\mathbf{S}}(t-1)-\mathrm{E}_{\overline\sigma}(\psi,t-j){\mathbf{S}}(j)+ {\mathbf{S}}(t-1)\big[\mathrm{E}_{\overline\sigma}(\psi,t-j) -\mathrm{E}_{\overline\sigma}(\psi,1)\big]\big)\Big\}\\ & = \underbrace{\underbrace{\frac{ab(\sigma)}{1-\sigma}}_{ > 0}\underbrace{\mathrm{E}_{\overline\sigma}(\psi,t-j)}_{ > 0}\big[\underbrace{{\mathbf{S}}(t-1)-{\mathbf{S}}(j)}_{\geq 0}\big]}_{\geq 0}. \end{split} \end{equation} (5.21)

    The outcome is therefore proved. We may also prove it for the other compartments in our suggested model.

    Remark 5.3. By equivalent requirements with their accompanying difference operators, the approach outlined above may also be utilized to get all of the aforementioned outcomes for decreasing (or strictly decreasing) functions.

    Theorem 5.3. [38] For \sigma\in(0, \frac{1}{2}) , the following results hold true:

    \begin{equation} \begin{cases} {}_j^{ab}\nabla^{-\sigma}\{\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{S}}(t)\} = {\mathbf{S}}(t)-{\mathbf{S}}(j),\\ {}_j^{ab}\nabla^{-\sigma}\{\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{E}}(t)\} = {\mathbf{E}}(t)-{\mathbf{E}}(j),\\ {}_j^{ab}\nabla^{-\sigma}\{\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{A}}(t)\} = {\mathbf{A}}(t)-{\mathbf{A}}(j),\\ {}_j^{ab}\nabla^{-\sigma}\{\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{C}}(t)\} = {\mathbf{C}}(t)-{\mathbf{C}}(j),\\ {}_j^{ab}\nabla^{-\sigma}\{\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{T}}(t)\} = {\mathbf{T}}(t)-{\mathbf{T}}(j),\\ {}_j^{ab}\nabla^{-\sigma}\{\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{R}}(t)\} = {\mathbf{R}}(t)-{\mathbf{R}}(j). \end{cases} \end{equation} (5.22)

    and

    \begin{equation} \begin{cases} {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{S}}(t)\} = {\mathbf{S}}(t)-{\mathbf{S}}(j)\mathrm{E}_{\overline{\sigma}}(\psi,t-j),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{E}}(t)\} = {\mathbf{E}}(t)-{\mathbf{E}}(j)\mathrm{E}_{\overline{\sigma}}(\psi,t-j),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{A}}(t)\} = {\mathbf{A}}(t)-{\mathbf{A}}(j)\mathrm{E}_{\overline{\sigma}}(\psi,t-j),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{C}}(t)\} = {\mathbf{C}}(t)-{\mathbf{C}}(j)\mathrm{E}_{\overline{\sigma}}(\psi,t-j),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{T}}(t)\} = {\mathbf{T}}(t)-{\mathbf{T}}(j)\mathrm{E}_{\overline{\sigma}}(\psi,t-j),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{R}}(t)\} = {\mathbf{R}}(t)-{\mathbf{R}}(j)\mathrm{E}_{\overline{\sigma}}(\psi,t-j), \end{cases} \end{equation} (5.23)

    for t\in\mathrm{N}_{j+1} .

    Proof. Define the following \forall t\in\mathrm{N}_{j+1} :

    \begin{equation} \begin{cases} {}_j^{mabc}\nabla^{\sigma}{\mathbf{S}}(t) = \Psi_1(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{E}}(t) = \Psi_2(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{A}}(t) = \Psi_3(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{C}}(t) = \Psi_4(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{T}}(t) = \Psi_5(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ {}_j^{mabc}\nabla^{\sigma}{\mathbf{R}}(t) = \Psi_6(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}). \end{cases} \end{equation} (5.24)

    Taking discrete Laplace transform \curlywedge_j on both sides of first equation of (5.24) and utilizing Lemma (2.4), we have

    \begin{align} \frac{ab(\sigma)}{1-\sigma}\Big[{\mathbf{S}}(\omega)-\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma}-\psi}{\mathbf{S}}(j)+ \frac{\psi}{\omega^{\sigma}-\psi}{\mathbf{S}}(\omega)\Big]& = \Psi_1(\omega,\mathrm{S,E,A,C,T,R})\\ \frac{ab(\sigma)}{1-\sigma}\Big[\frac{\omega^{\sigma}}{\omega^{\sigma}-\psi}{\mathbf{S}}(\omega) -\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma}-\psi}{\mathbf{S}}(j)\Big]& = \Psi_1(\omega,\mathrm{S,E,A,C,T,R}). \end{align} (5.25)

    Solving for {\mathbf{S}}(\omega) , we have

    \begin{equation} {\mathbf{S}}(\omega) = \Big(\frac{1-\sigma}{ab(\sigma)}+\frac{\sigma}{ab(\sigma)\omega^{\sigma}}\Big)\Psi_1(\omega,\mathrm{S,E,A,C,T,R}) +\frac{(1-\omega)^\sigma}{\omega}{\mathbf{S}}(j). \end{equation} (5.26)

    It follows from [38] that

    \begin{equation} {\mathbf{S}}(\omega) = \curlywedge_j[\ {}_j^{ab}\nabla^{-\sigma}\Psi_1(\omega,\mathrm{S,E,A,C,T,R})]+\frac{(1-\omega)^\sigma}{\omega}{\mathbf{S}}(j). \end{equation} (5.27)

    Taking discrete inverse Laplace transform on both sides of (5.27), we have

    \begin{equation} {\mathbf{S}}(t) = {}_j^{ab}\nabla^{-\sigma}\{\Psi_1(t,{\mathbf{S,E,A,C,T,R}})\}+{\mathbf{S}}(j) = {}_j^{ab}\nabla^{-\sigma}\{{}_j^{mabc}\nabla^{\sigma}{\mathbf{S}}(t)\}+{\mathbf{S}}(j). \end{equation} (5.28)

    Also, we can find

    \begin{equation} \begin{cases} {\mathbf{E}}(t) = {}_j^{ab}\nabla^{-\sigma}\{\Psi_2(t,{\mathbf{S,E,A,C,T,R}})\}+{\mathbf{E}}(j) = {}_j^{ab}\nabla^{-\sigma}\{{}_j^{mabc}\nabla^{\sigma}{\mathbf{E}}(t)\}+{\mathbf{E}}(j),\\ {\mathbf{A}}(t) = {}_j^{ab}\nabla^{-\sigma}\{\Psi_3(t,{\mathbf{S,E,A,C,T,R}})\}+{\mathbf{A}}(j) = {}_j^{ab}\nabla^{-\sigma}\{{}_j^{mabc}\nabla^{\sigma}{\mathbf{A}}(t)\}+{\mathbf{A}}(j),\\ {\mathbf{C}}(t) = {}_j^{ab}\nabla^{-\sigma}\{\Psi_4(t,{\mathbf{S,E,A,C,T,R}})\}+{\mathbf{C}}(j) = {}_j^{ab}\nabla^{-\sigma}\{{}_j^{mabc}\nabla^{\sigma}{\mathbf{C}}(t)\}+{\mathbf{C}}(j),\\ {\mathbf{T}}(t) = {}_j^{ab}\nabla^{-\sigma}\{\Psi_5(t,{\mathbf{S,E,A,C,T,R}})\}+{\mathbf{T}}(j) = {}_j^{ab}\nabla^{-\sigma}\{{}_j^{mabc}\nabla^{\sigma}{\mathbf{T}}(t)\}+{\mathbf{T}}(j),\\ {\mathbf{R}}(t) = {}_j^{ab}\nabla^{-\sigma}\{\Psi_6(t,{\mathbf{S,E,A,C,T,R}})\}+{\mathbf{R}}(j) = {}_j^{ab}\nabla^{-\sigma}\{{}_j^{mabc}\nabla^{\sigma}{\mathbf{R}}(t)\}+{\mathbf{R}}(j). \end{cases} \end{equation} (5.29)

    The first portion of the theorem is satisfied.

    Now let \forall t\in\mathrm{N}_{j+1}

    \begin{equation} \begin{cases} {}_j^{ab}\nabla^{-\sigma}{\mathbf{S}}(t) = \Upsilon_1(t,{\mathbf{S,E,A,C,T,R}}), \\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{E}}(t) = \Upsilon_2(t,{\mathbf{S,E,A,C,T,R}}), \\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{A}}(t) = \Upsilon_3(t,{\mathbf{S,E,A,C,T,R}}), \\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{C}}(t) = \Upsilon_4(t,{\mathbf{S,E,A,C,T,R}}), \\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{T}}(t) = \Upsilon_5(t,{\mathbf{S,E,A,C,T,R}}), \\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{R}}(t) = \Upsilon_6(t,{\mathbf{S,E,A,C,T,R}}). \end{cases} \end{equation} (5.30)
    \begin{equation} \Rightarrow \begin{cases} {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{S}}(t)\} = {}_j^{mabc}\nabla^{\sigma}\Upsilon_1(t,{\mathbf{S,E,A,C,T,R}}),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{E}}(t)\} = {}_j^{mabc}\nabla^{\sigma}\Upsilon_2(t,{\mathbf{S,E,A,C,T,R}}),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{A}}(t)\} = {}_j^{mabc}\nabla^{\sigma}\Upsilon_3(t,{\mathbf{S,E,A,C,T,R}}),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{C}}(t)\} = {}_j^{mabc}\nabla^{\sigma}\Upsilon_4(t,{\mathbf{S,E,A,C,T,R}}),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{T}}(t)\} = {}_j^{mabc}\nabla^{\sigma}\Upsilon_5(t,{\mathbf{S,E,A,C,T,R}}),\\ {}_j^{mabc}\nabla^{\sigma}\{\ {}_j^{ab}\nabla^{-\sigma}{\mathbf{R}}(t)\} = {}_j^{mabc}\nabla^{\sigma}\Upsilon_6(t,{\mathbf{S,E,A,C,T,R}}). \end{cases} \end{equation} (5.31)

    Applying discrete Laplace transform \curlywedge_j on {}_j^{mabc}\nabla^{\sigma}\Upsilon_1 , we get

    \begin{equation} \curlywedge_j\{ {}_j^{mabc}\nabla^{\sigma}\Upsilon_1(t,{\mathbf{S,E,A,C,T,R}}]\} = \frac{ab(\sigma)}{1-\sigma}\Big[\frac{\omega^{\sigma}}{\omega^{\sigma} -\psi}\Upsilon_1(\omega,\mathrm{S,E,A,C,T,R}) -\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma}-\psi}\Upsilon_1(j)\Big]. \end{equation} (5.32)

    From (5.26) and (5.27), we have

    \begin{equation} \Upsilon_1(\omega,\mathrm{S,E,A,C,T,R}) = \frac{1-\sigma}{ab(\sigma)}{\mathbf{S}}(\omega)+\frac{\sigma}{ab(\sigma){\omega^{\sigma}}}{\mathbf{S}}(\omega). \end{equation} (5.33)

    Also, from (2.19), we find

    \begin{equation} \Upsilon_1(j) = {}_j^{ab}{\nabla}^{-\sigma}{\mathbf{S}}(j) = \frac{1-\sigma}{ab(\sigma)}{\mathbf{S}}(j). \end{equation} (5.34)

    Equation (5.32) becomes:

    \begin{align} \curlywedge_j\{ {}_j^{mabc}\nabla^{\sigma}&\Upsilon_1(t,{\mathbf{S,E,A,C,T,R}})\}\\ & = \frac{ab(\sigma)}{1-\sigma}\Big[\frac{\omega^{\sigma}}{\omega^{\sigma} -\psi}\big(\frac{1-\sigma}{ab(\sigma)}+\frac{\sigma}{ab(\sigma){\omega^{\sigma}}}\big){\mathbf{S}}(\omega) -\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma}-\psi}\big(\frac{1-\sigma}{ab(\sigma)}\big){\mathbf{S}}(j)\Big]\\ & = {\mathbf{S}}(\omega) -\Big(\frac{\omega^{\sigma-1} (1-\omega)^{\sigma}}{\omega^{\sigma}-\psi}\Big){\mathbf{S}}(j). \end{align} (5.35)

    Taking inverse Laplace transform on both sides of (5.35), we find

    \begin{equation} {}_j^{mabc}\nabla^{\sigma}\Upsilon_1(t,{\mathbf{S,E,A,C,T,R}}) = {\mathbf{S}}(t)- {\mathbf{S}}(j)\curlywedge_j^{-1}\Big[\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma} -\psi}\Big] = {\mathbf{S}}(t)- \mathrm{E}_{\overline{\sigma}}\; (\psi,t-j){\mathbf{S}}(j),\\ \end{equation} (5.36)

    and, also,

    \begin{equation} \begin{cases} {}_j^{mabc}\nabla^{\sigma}\Upsilon_2(t,{\mathbf{S,E,A,C,T,R}}) = {\mathbf{E}}(t)- {\mathbf{E}}(j)\curlywedge_j^{-1}\Big[\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma} -\psi}\Big] = {\mathbf{E}}(t)- \mathrm{E}_{\overline{\sigma}}\; (\psi,t-j){\mathbf{E}}(j),\\ {}_j^{mabc}\nabla^{\sigma}\Upsilon_3(t,{\mathbf{S,E,A,C,T,R}}) = {\mathbf{A}}(t)- {\mathbf{A}}(j)\curlywedge_j^{-1}\Big[\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma} -\psi}\Big] = {\mathbf{A}}(t)- \mathrm{E}_{\overline{\sigma}}\; (\psi,t-j){\mathbf{A}}(j),\\ {}_j^{mabc}\nabla^{\sigma}\Upsilon_4(t,{\mathbf{S,E,A,C,T,R}}) = {\mathbf{C}}(t)- {\mathbf{C}}(j)\curlywedge_j^{-1}\Big[\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma} -\psi}\Big] = {\mathbf{C}}(t)- \mathrm{E}_{\overline{\sigma}}\; (\psi,t-j){\mathbf{C}}(j),\\ {}_j^{mabc}\nabla^{\sigma}\Upsilon_5(t,{\mathbf{S,E,A,C,T,R}}) = {\mathbf{T}}(t)- {\mathbf{T}}(j)\curlywedge_j^{-1}\Big[\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma} -\psi}\Big] = {\mathbf{T}}(t)- \mathrm{E}_{\overline{\sigma}}\; (\psi,t-j){\mathbf{T}}(j),\\ {}_j^{mabc}\nabla^{\sigma}\Upsilon_6(t,{\mathbf{S,E,A,C,T,R}}) = {\mathbf{R}}(t)- {\mathbf{R}}(j)\curlywedge_j^{-1}\Big[\frac{\omega^{\sigma-1}(1-\omega)^{\sigma}}{\omega^{\sigma} -\psi}\Big] = {\mathbf{R}}(t)- \mathrm{E}_{\overline{\sigma}}\; (\psi,t-j){\mathbf{R}}(j). \end{cases} \end{equation} (5.37)

    In view of Eq (5.30), the second portion of the theorem is satisfied.

    Theorem 5.2. [38] The following outcome offers a different series representation of the discrete modified Atangana-Baleanu of the Liouville-Caputo-type fractional difference for \sigma\in(0, \frac{1}{2}) , which is:

    \begin{equation} \begin{cases} {}_j^{mabc}\nabla^{\sigma}{{\mathbf{S}}}(t) = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{S}}}(t)-{{\mathbf{S}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big(\ {}_j\nabla^{-(\sigma k+\sigma)}{{\mathbf{S}}}(t)\big)\Big],\\ {}_j^{mabc}\nabla^{\sigma}{{\mathbf{E}}}(t) = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{E}}}(t)-{{\mathbf{E}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big(\ {}_j\nabla^{-(\sigma k+\sigma)}{{\mathbf{E}}}(t)\big)\Big],\\ {}_j^{mabc}\nabla^{\sigma}{{\mathbf{A}}}(t) = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{A}}}(t)-{{\mathbf{A}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big(\ {}_j\nabla^{-(\sigma k+\sigma)}{{\mathbf{A}}}(t)\big)\Big],\\ {}_j^{mabc}\nabla^{\sigma}{{\mathbf{C}}}(t) = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{C}}}(t)-{{\mathbf{C}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big(\ {}_j\nabla^{-(\sigma k+\sigma)}{{\mathbf{C}}}(t)\big)\Big],\\ {}_j^{mabc}\nabla^{\sigma}{{\mathbf{T}}}(t) = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{T}}}(t)-{{\mathbf{T}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big(\ {}_j\nabla^{-(\sigma k+\sigma)}{{\mathbf{T}}}(t)\big)\Big],\\ {}_j^{mabc}\nabla^{\sigma}{{\mathbf{R}}}(t) = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{R}}}(t)-{{\mathbf{R}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big(\ {}_j\nabla^{-(\sigma k+\sigma)}{{\mathbf{R}}}(t)\big)\Big], \end{cases} \end{equation} (5.38)

    for t\in\mathrm{N}_{a+1} .

    Proof. From Definitions 2.2 and 2.8, we have

    \begin{equation} \begin{split} {}_j^{mabc}\nabla^{\sigma}{{\mathbf{S}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{S}}}(t)-{{\mathbf{S}}}(j) \; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) +\psi \sum\limits_{\omega = j+1}^{t}\mathrm{E}_{\overline{\sigma,\sigma}}(\psi,t+1-\omega){{\mathbf{S}}}(\omega)\Big]\\ & = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{S}}}(t)-{{\mathbf{S}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) +\psi \sum\limits_{\omega = j+1}^{t} \sum\limits_{k = 0}^{\infty}{\psi}^{k}\frac{(t+1-\omega)^{\overline{\sigma k+\sigma+1}}}{\Gamma(\sigma k+\sigma)}{{\mathbf{S}}}(\omega)\Big]\\ & = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{S}}}(t)-{{\mathbf{S}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}\psi^{k+1}\frac{1}{\Gamma(\sigma k+\sigma)} \sum\limits_{\omega = a+1}^{t}(t+1-\omega)^{\overline{\sigma k+\sigma+1}}{{\mathbf{S}}}(\omega)\Big]\\ & = \frac{ab(\sigma)}{1-\sigma}\Big[{{\mathbf{S}}}(t)-{{\mathbf{S}}}(j)\; \mathrm{E}_{\overline{\sigma}}(\psi,t-j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big\{\ {}_j\nabla^{-(\sigma k+\sigma)}{{\mathbf{S}}}(t)\big\}\Big]. \end{split} \end{equation} (5.39)

    We can demonstrate it for all of the compartments in our suggested system by means of the same approach.

    Our suggested system can be expressed as

    \begin{eqnarray} {}_{j}^{mabc}\nabla^{\sigma}[{\mathbf{S}}(t)]& = & \varpi_1(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}), \\ {}_{j}^{mabc}\nabla^{\sigma}[{\mathbf{E}}(t)]& = & \varpi_2(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}), \\ {}_{j}^{mabc}\nabla^{\sigma}[{\mathbf{A}}(t)]& = & \varpi_3(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}), \\ {}_{j}^{mabc}\nabla^{\sigma}[{\mathbf{C}}(t)]& = & \varpi_4(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}),\\ {}_{j}^{mabc}\nabla^{\sigma}[{\mathbf{T}}(t)]& = & \varpi_5(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}), \\ {}_{j}^{mabc}\nabla^{\sigma}[{\mathbf{R}}(t)]& = & \varpi_6(t,{\mathbf{S}},{\mathbf{E}},{\mathbf{A}},{\mathbf{C}},{\mathbf{T}},{\mathbf{R}}). \end{eqnarray} (6.1)

    From Theorem 5.2, we obtain

    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{S}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_1(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_1}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big[\ {}_{j}\nabla^{-(\sigma k+\sigma)}{\varpi_1}(t)\big]\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{E}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_2(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_2}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big[\ {}_{j}\nabla^{-(\sigma k+\sigma)}{\varpi_2}(t)\big]\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{A}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_3(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_3}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big[\ {}_{j}\nabla^{-(\sigma k+\sigma)}{\varpi_3}(t)\big]\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{C}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_4(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_4}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big[\ {}_{j}\nabla^{-(\sigma k+\sigma)}{\varpi_4}(t)\big]\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{T}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_5(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_5}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big[\ {}_{j}\nabla^{-(\sigma k+\sigma)}{\varpi_5}(t)\big]\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{R}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_6(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_6}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1}\big[\ {}_{j}\nabla^{-(\sigma k+\sigma)}{\varpi_6}(t)\big]\Big],\\ \end{split} \end{equation} (6.2)
    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{S}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_1(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_1}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1} \ \frac{(t-j)^{\overline{\sigma k+\sigma}}}{\Gamma(\sigma k+\sigma+1)}\varpi_1(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{E}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_2(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_2}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1} \ \frac{(t-j)^{\overline{\sigma k+\sigma}}}{\Gamma(\sigma k+\sigma+1)}\varpi_2(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{A}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_3(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_3}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1} \ \frac{(t-j)^{\overline{\sigma k+\sigma}}}{\Gamma(\sigma k+\sigma+1)}\varpi_3(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{C}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_4(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_4}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1} \ \frac{(t-j)^{\overline{\sigma k+\sigma}}}{\Gamma(\sigma k+\sigma+1)}\varpi_4(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{T}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_5(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_5}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1} \ \frac{(t-j)^{\overline{\sigma k+\sigma}}}{\Gamma(\sigma k+\sigma+1)}\varpi_5(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{R}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_6(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_6}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k+1} \ \frac{(t-j)^{\overline{\sigma k+\sigma}}}{\Gamma(\sigma k+\sigma+1)}\varpi_6(t)\Big]. \end{split} \end{equation} (6.3)
    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{S}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_1(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_1}(j) + \sum\limits_{k = 1}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_1(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{E}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_2(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_2}(j) + \sum\limits_{k = 1}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_2(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{A}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_3(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_3}(j) + \sum\limits_{k = 1}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_3(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{C}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_4(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_4}(j) + \sum\limits_{k = 1}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_4(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{T}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_5(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_5}(j) + \sum\limits_{k = 1}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_5(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{R}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[\varpi_6(t)-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_6}(j) + \sum\limits_{k = 1}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_6(t)\Big]. \end{split} \end{equation} (6.4)
    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{S}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_1}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_1(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{E}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_2}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_2(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{A}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_3}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_3(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{C}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_4}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_4(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{T}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_5}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_5(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{R}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_6}(j) + \sum\limits_{k = 0}^{\infty}{\psi}^{k} \ \frac{(t-j)^{\overline{\sigma k}}}{\Gamma(\sigma k+1)}\varpi_6(t)\Big]. \end{split} \end{equation} (6.5)
    \begin{equation} \begin{split} {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{S}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_1}(j) +\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_1}(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{E}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_2}(j) +\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_2}(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{A}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_3}(j) +\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_3}(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{C}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_4}(j) +\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_4}(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{T}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_5}(j) +\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_5}(t)\Big],\\ {}_{j}^{mabc}\nabla^{\sigma}{{\mathbf{R}}}(t)& = \frac{ab(\sigma)}{1-\sigma}\Big[-\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_6}(j) +\mathrm{E}_{\overline{\sigma}}(\psi,t-j){\varpi_6}(t)\Big]. \end{split} \end{equation} (6.6)

    Discrete generalized Mittag-Leffler kernels were used in this study to develop a fractional-order model of the HBV epidemic. It addressed the existence and uniqueness of solutions, the positively invariant region, equilibrium states analysis, the fundamental reproduction number, and positivity and boundedness of solutions. A lyapunov function was also used to investigate the global asymptotic stability of the model. The variables that responded the best to the fundamental reproduction number underwent sensitivity analysis. To minimize the number of variables and streamline the issue for optimization, monotonicity analysis is utilized. In specific time scale domains, the study demonstrated that the proposed discrete fractional operators will exhibit \chi^2 -increasing or decreasing behavior, allowing for effective control of HBV, based on their fundamental features and \chi -monotonicity descriptions. The study proposes that the dynamics of hepatitis B in society could be monitored through numerical simulations. The two factors that most inhibit the spread of the disease are vaccination and treatment rates. Raising these rates for both chronically ill patients and newborns is a highly efficient way to halt the spread of HBV. Vaccination, efficient treatment, and stopping the virus's spread all work together to make infection elimination conceivable as well as even possible. Integer-order models lack memory and hereditary properties, while fractional-order models possess these properties. Fractional-order models offer more freedom in derivative order, allowing for more exploration of disease dynamics and memory effects on specific datasets, unlike integer-order models. The proposed model enhances the prediction capacity for the hepatitis B virus in this regard. Policymakers and public health professionals may find the results useful in stopping the spread of hepatitis B. The authors advise more research on the suggested model using a variety of mathematical approaches, such as topological degree theory and upper-lower solution methods, as well as a study of its numerical solution using a variety of numerical techniques.

    M. Farman: Conceptualization, Formal analysis, Writing-original draft, Writing review editing; A. Akgül: Conceptualization, Software, Visualization, Writing original draft; J. A. Conejero: Formal analysis, Supervision, Writing-original draft, Writing-review, editing; A. Shehzade: Formal analysis, Writing-original draft, Visualization, Writing-review editing; K. S. Sooppy: Formal analysis, Software, Formatting, Writing review, editing; D. Baleanu: Methodology, Formal analysis, Visualization. All authors have read and approved the final version of the manuscript for publication.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    Prof. J. A. Conejero is the Guest Editor of special issue "Advances in Dynamical Systems and Applications" for AIMS Mathematics. He was not involved in the editorial review and the decision to publish this article. The authors declare no conflict of interest.



    [1] P. Zhou, X. Yang, X. Wang, B. Hu, L. Zhang, W. Zhang, et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579 (2020), 270–273. doi: 10.1038/s41586-020-2012-7
    [2] J. K. Y. Yap, M. Moriyama, A. Iwasaki, Inflammasomes and pyroptosis as therapeutic targets for COVID-19, J. Immunol., 205 (2020), 307–312. doi: 10.4049/jimmunol.2000513
    [3] M. Z. Tay, C. M. Poh, L. Rénia, P. A. MacAry, L. F. P. Ng, The trinity of COVID-19: Immunity, inflammation and intervention, Nat. Rev. Immunol., 579 (2020), 363–374.
    [4] M. Soy, G. Keser, P. Atagündüz, F. Tabak, I. Atagündüz, S. Kayhan, Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment, Clin. Rheumatol., 39 (2020), 2085–2094. doi: 10.1007/s10067-020-05190-5
    [5] D. Tang, P. Comish, R. Kang, The hallmarks of COVID-19 disease, PLoS Pathog., 16 (2020), e1008536. doi: 10.1371/journal.ppat.1008536
    [6] A. Shah, Novel coronavirus-induced NLRP3 inflammasome activation: A potential drug target in the treatment of COVID-19, Front. Immunol., 11 (2020), 1021. doi: 10.3389/fimmu.2020.01021
    [7] M. Z. Ratajczak, M. Kucia, SARS-CoV-2 infection and overactivation of NLRP3 inflammasome as a trigger of cytokine storm and risk factor for damage of hematopoietic stem cells, Leukemia, 4 (2020), 1726–1729.
    [8] Y. Fu, Y. Cheng, Y. Wu, Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools, Virol. Sin., 35 (2020), 266–271. doi: 10.1007/s12250-020-00207-4
    [9] S. Nagashima, M. C. Mendes, A. P. Camargo, N. H. Borges, T. M. Godoy, A. F. R. Miggiolaro, et al., Endothelial dysfunction and thrombosis in patients with COVID-19-brief report, Arterioscler. Thromb. Vasc. Biol., 40 (2020), 2404–2407. doi: 10.1161/ATVBAHA.120.314860
    [10] Y. Jamilloux, T. Henry, A. Belot, S. Viel, M. Fauter, T. El Jammal, et al., Should we stimulate or suppress immune responses in COVID-19: Cytokine and anti-cytokine interventions, Autoimmun. Rev., 19 (2020), 102567. doi: 10.1016/j.autrev.2020.102567
    [11] C. Y. Taabazuing, M. C. Okondo, D. A. Bachovchin, Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages, Cell Chem. Biol., 24 (2017), 507–514. doi: 10.1016/j.chembiol.2017.03.009
    [12] N. Kelley, D. Jeltema, Y. Duan, Y. He, The NLRP3 inflammasome: An overview of mechanisms of activation and regulation, Int. J. Mol. Sci., 20 (2019), 3328. doi: 10.3390/ijms20133328
    [13] T. Bergsbaken, S. L. Fink, B. T. Cookson, Pyroptosis: Host cell death and inflammation, Nat. Rev. Microbiol., 7 (2009), 99–109. doi: 10.1038/nrmicro2070
    [14] C. A. Dinarello, Immunological and inflammatory functions of the interleukin-1 family, Annu. Rev. Immunol., 27 (2009), 519–550. doi: 10.1146/annurev.immunol.021908.132612
    [15] Y. He, H. Hara, G. Núñez, Mechanism and regulation of NLRP3 inflammasome activation, Trends Biochem. Sci., 41 (2016), 1012–1021. doi: 10.1016/j.tibs.2016.09.002
    [16] Z. B. Zalinger, R. Elliott, S.R. Weiss, Role of the inflammasome-related cytokines IL-1 and IL-18 during infection with murine coronavirus, J. Neurovirol., 23 (2017), 845–854. doi: 10.1007/s13365-017-0574-4
    [17] A. Stutz, D. T. Golenbock, E. Latz, Inflammasomes: Too big to miss, J. Clin. Invest., 119 (2009), 3502–3511. doi: 10.1172/JCI40599
    [18] J. J. O'Shea, M. Gadina, R. M. Siegel, J. Farber, Cytokines, in Rheumatology, (2015), 99–112.
    [19] P. Song, W. Li, J. Xie, Y. Hou, C. You, Cytokine storm induced by SARS-CoV-2, Clin. Chim. Acta, 509 (2020), 280–287. doi: 10.1016/j.cca.2020.06.017
    [20] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet, 395 (2020), 497–506. doi: 10.1016/S0140-6736(20)30183-5
    [21] M. Bertinaria, S. Gastaldi, E. Marini, M. Giorgis, Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity, Arch. Biochem. Biophys., 670 (2019), 116–139. doi: 10.1016/j.abb.2018.11.013
    [22] K. Tsuchiya, Inflammasome-associated cell death: Pyroptosis, apoptosis, and physiological implications, Microbiol. Immunol., 64 (2020), 252–269. doi: 10.1111/1348-0421.12771
    [23] S. L. Fink, B. T. Cookson, Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells, Infect. Immun., 73 (2005), 1907–1916. doi: 10.1128/IAI.73.4.1907-1916.2005
    [24] A. G. Kozloski, Inflammasome, Mater. Methods, 10 (2020), 2869.
    [25] S. Christgen, D. E. Place, T. D. Kanneganti, Toward targeting inflammasomes: Insights into their regulation and activation, Cell Res., 30 (2020), 315–327. doi: 10.1038/s41422-020-0295-8
    [26] Z. Zheng, G. Li, Mechanisms and therapeutic regulation of pyroptosis in inflammatory diseases and cancer, Int. J. Mol. Sci., 21 (2020), 1456. doi: 10.3390/ijms21041456
    [27] M. G. Sanders, M. J. Parsons, A. G. Howard, J. Liu, S. R. Fassio, J. A. Martinez, et al., Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes, Cell Death Dis., 6 (2015), e1813. doi: 10.1038/cddis.2015.186
    [28] C. Semino, S. Carta, M. Gattorno, R. Sitia, A. Rubartelli, Progressive waves of IL-1\beta release by primary human monocytes via sequential activation of vesicular and gasdermin D-mediated secretory pathways, Cell Death Dis., 9 (2018), 1–14. doi: 10.1038/s41419-017-0012-9
    [29] G. Lopez-Castejon, D. Brough, Understanding the mechanism of IL-1\beta secretion, Cytokine Growth Factor Rev., 22 (2011), 189–195. doi: 10.1016/j.cytogfr.2011.10.001
    [30] P. Broz, P. Pelegrín, F. Shao, The gasdermins, a protein family executing cell death and inflammation, Nat. Rev. Immunol., 20 (2019), 143–157.
    [31] L. DiPeso, D. X. Ji, R. E. Vance, J. V. Price, Cell death and cell lysis are separable events during pyroptosis, Cell Death Dis., 3 (2017), 1–10.
    [32] D. Brough, N. J. Rothwell, Caspase-1-dependent processing of pro-interleukin-1\beta is cytosolic and precedes cell death, J. Cell Sci., 120 (2007), 772–781. doi: 10.1242/jcs.03377
    [33] K. Schleich, I. N. Lavrik, Mathematical modeling of apoptosis, Cell Comm. Signal., 11 (2013), 1–7. doi: 10.1186/1478-811X-11-1
    [34] S. L. Spencer, P. K. Sorger, Measuring and modeling apoptosis in single cells, Cell, 144 (2011), 926–939. doi: 10.1016/j.cell.2011.03.002
    [35] W. Wang, T. Zhang, Caspase-1-mediated pyroptosis of the predominance for driving CD4 T cells death: A nonlocal spatial mathematical model, Bull. Math. Biol., 80 (2018), 540–582. doi: 10.1007/s11538-017-0389-8
    [36] D. Veltman, T. Laeremans, E. Passante, H. J. Huber, Signal transduction analysis of the NLRP3-inflammasome pathway after cellular damage and its paracrine regulation, J. Theor. Biol., 415 (2017), 125–136. doi: 10.1016/j.jtbi.2016.12.016
    [37] Y. Bozkurt, A. Demir, B. Erman, A. Gül, Unified modeling of familial mediterranean fever and cryopyrin associated periodic syndromes, Comp. Math. Meth. Med., 15 (2015), 893507.
    [38] F. López-Caamal, H. J. Huber, Stable IL-1\beta-activation in an inflammasome signalling model depends on positive and negative-feedbacks and tight regulation of protein production, IEEE ACM T. Comput. Bi., 16 (2018), 627–637.
    [39] WHO, World Health Organisation Statement on the Pandemic, 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–-11-march-2020.
    [40] F. Akpinar, B. Inankur, J. Yin, Spatial-temporal patterns of viral amplification and interference initiated by a single infected cell, J. Virol., 90 (2016), 7552–7566. doi: 10.1128/JVI.00807-16
    [41] A. Bankhead, E. Mancini, A. C. Sims, R. S. Baric, S. McWeeney, P. M. A. Sloot, A simulation framework to investigate in vitro viral infection dynamics, J. Comput. Sci., 4 (2013), 127–134. doi: 10.1016/j.jocs.2011.08.007
    [42] A. L. Bauer, C. Beauchemin, A. S. Perelson, Agent-based modeling of host–pathogen systems: The successes and challenges, Inf. Sci., 179 (2009), 1379–1389. doi: 10.1016/j.ins.2008.11.012
    [43] G. Bocharov, A. Meyerhans, N. Bessonov, S. Trofimchuk, V. Volpert, Spatiotemporal dynamics of virus infection spreading in tissues, PLoS One, 11 (2016), e0168576. doi: 10.1371/journal.pone.0168576
    [44] C. Beauchemin, S. Forrest, F. T. Koster, Modeling influenza viral dynamics in tissue, in International Conference on Artificial Immune Systems (Springer), (2006), 23–36.
    [45] C. Beauchemin, Probing the effects of the well-mixed assumption on viral infection dynamics, J. Theor. Biol., 242 (2006), 464–477. doi: 10.1016/j.jtbi.2006.03.014
    [46] C. Beauchemin, J. Samuel, J. Tuszynski, A simple cellular automaton model for influenza A viral infections, J. Theor. Biol., 232 (2005), 223–234. doi: 10.1016/j.jtbi.2004.08.001
    [47] D. Levin, S. Forrest, S. Banerjee, C. Clay, J. Cannon, M. Moses, et al., A spatial model of the efficiency of T cell search in the influenza-infected lung, J. Theor. Biol., 398 (2016), 52–63. doi: 10.1016/j.jtbi.2016.02.022
    [48] N. Fachada, V. V. Lopes, A. Rosa, Simulating antigenic drift and shift in influenza A, in Proceedings of the 2009 ACM symposium on Applied Computing, (2009), 2093–2100.
    [49] A. L. Jenner, F. Frascoli, A. C. F. Coster, P. S. Kim, Enhancing oncolytic virotherapy: Observations from a Voronoi cell-based model, J. Theor. Biol., 485 (2020), 110052. doi: 10.1016/j.jtbi.2019.110052
    [50] D. Wodarz, A. Hofacre, J. W. Lau, Z. Sun, H. Fan, N. L. Komarova, Complex spatial dynamics of oncolytic viruses in vitro: Mathematical and experimental approaches, PLoS Comput. Biol., 8 (2012), e1002547. doi: 10.1371/journal.pcbi.1002547
    [51] G. An, Introduction of an agent-based multi-scale modular architecture for dynamic knowledge representation of acute inflammation, Theor. Biol. Med., 5 (2008), 11. doi: 10.1186/1742-4682-5-11
    [52] R. C. Cockrell, G. An, Examining the controllability of sepsis using genetic algorithms on an agent-based model of systemic inflammation, PLoS Comput. Biol., 14 (2018), e1005876. doi: 10.1371/journal.pcbi.1005876
    [53] F. Fatehi, R. J. Bingham, E. C. Dykeman, P. G. Stockley, R. Twarock, Comparing antiviral strategies against COVID-19 via multi-scale within host modelling, preprint, arXiv: 2010.08957.
    [54] T. J. Sego, J. O. Aponte-Serrano, J. F. Gianlupi, S. R. Heaps, K. Breithaupt, L. Brusch, et al., A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness, PLoS Comput. Biol., 16 (2020), e1008451. doi: 10.1371/journal.pcbi.1008451
    [55] Y. Wang, G. An, A. Becker, C. Cockrell, N. Collier, M. Craig, et al., Rapid community-driven development of a SARS-CoV-2 tissue simulator, preprint, bioR\chiiv: 2020.04.02.019075. Available from: https://www.biorxiv.org/content/10.1101/2020.04.02.019075v3.
    [56] A. V. Bagaev, A. Y. Garaeva, E. S. Lebedeva, A. V. Pichugin, R. I. Ataullakhanov, F. I. Ataullakhanov, Elevated pre-activation basal level of nuclear NF-\kappaB in native macrophages accelerates LPS-induced translocation of cytosolic NF-\kappaB into the cell nucleus, Sci. Reports, 9 (2019), 1–16.
    [57] C. Zhang, C. Zhao, X. Chen, R. Tao, S. Wang, G. Meng, et al., Induction of ASC pyroptosis requires gasdermin D or caspase-1/11-dependent mediators and IFN\beta from pyroptotic macrophages, Cell Death Dis., 11 (2020), 470. doi: 10.1038/s41419-020-2664-0
    [58] Y. Huang, H. Jiang, Y. Chen, X. Wang, Y. Yang, J. Tao, et al., Tranilast directly targets NLRP3 to treat inflammasome-driven diseases, EMBO Mol. Med., 10 (2018), e8689.
    [59] M. S. Salahudeen, P. S. Nishtala, An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice, Saudi Pharm. J., 25 (2017), 165–175. doi: 10.1016/j.jsps.2016.07.002
    [60] N. M. de Vasconcelos, N. Van Opdenbosch, H. Van Gorp, E. Parthoens, M. Lamkanfi, Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture, Cell Death Diff., 26 (2019), 146–161. doi: 10.1038/s41418-018-0106-7
    [61] S. Han, T. B. Lear, J. A. Jerome, S. Rajbhandari, C. A. Snavely, D. L. Gulick, et al., Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase, J. Bio. Chem., 290 (2015), 18124–18133. doi: 10.1074/jbc.M115.645549
    [62] J. Cheng, A. L. Waite, E. R., Tkaczyk, K. Ke, N. Richards, A. J. Hunt, et al., Kinetic properties of ASC protein aggregation in epithelial cells, J. Cell. Physiol., 222 (2010), 738–747.
    [63] J. Ruland, Inflammasome: Putting the pieces together, Cell, 156 (2014), 1127–1129. doi: 10.1016/j.cell.2014.02.038
    [64] J. Chai, Y. Shi, Apoptosome and inflammasome: Conserved machineries for caspase activation, Nat. Sci. Rev., 1 (2014), 101–118. doi: 10.1093/nsr/nwt025
    [65] A. Iliev, N. Kyurkchiev, S. Markov, On the approximation of the step function by some sigmoid functions, Math. Comput. Simul., 133 (2017), 223–234. doi: 10.1016/j.matcom.2015.11.005
    [66] MATLAB, version 1.8.0_202 (R2019n). The MathWorks Inc., Natick, Massachusetts, 2019.
    [67] M. A. Moors, S. B. Mizel, Proteasome-mediated regulation of interleukin-1\beta turnover and export in human monocytes, J. Leukocyte Biol., 68 (2000), 131–136.
    [68] F. Martín-Sánchez, C. Diamond, M. Zeitler, A. I. Gomez, A. Baroja-Mazo, J. Bagnall, et al., Inflammasome-dependent IL-1\beta release depends upon membrane permeabilisation, Cell Death Diff., 23 (2016), 1219–1231. doi: 10.1038/cdd.2015.176
    [69] G. Qian, A. Mahdi, Sensitivity analysis methods in the biomedical sciences, Math Biosci., 323 (2020), 108306. doi: 10.1016/j.mbs.2020.108306
    [70] S. Hamis, S. Stratiev, G. G. Powathil, Uncertainty and sensitivity analyses methods for agent-based mathematical models: An introductory review, in The Physics of Cancer: Research Advances (ed. Bernard Gerstman), Singapore: World Scientific Publishing, 2021.
    [71] R. P. Dickinson, R. J. Gelinas, Sensitivity analysis of ordinary differential equation systems - A direct method, J. Comput. Phys., 21 (1976), 123–143. doi: 10.1016/0021-9991(76)90007-3
    [72] A. Ghaffarizadeh, R. Heiland, S. H. Friedman, S. M. Mumenthaler, P. Macklin, PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems, PLoS Comput. Biol., 14 (2018), e1005991. doi: 10.1371/journal.pcbi.1005991
    [73] K. Lipinska, K. E. Malone, M. Moerland, C. Kluft, Applying caspase-1 inhibitors for inflammasome assays in human whole blood, J. Immunol. Meth., 411 (2014), 66–69. doi: 10.1016/j.jim.2014.05.018
    [74] K. Schroder, J. Tschopp, The inflammasomes, Cell, 140 (2010), 821–832.
    [75] W. He, H. Wan, L. Hu, P. Chen, X. Wang, Z. Huang, et al., Gasdermin D is an executor of pyroptosis and required for interleukin-1\beta secretion, Cell Res., 25 (2015), 1285–1298. doi: 10.1038/cr.2015.139
    [76] S. Lee, M. Hirohama, M. Noguchi, K. Nagata, A. Kawaguchi, Influenza A virus infection triggers pyroptosis and apoptosis of respiratory epithelial cells through the type Ⅰ interferon signaling pathway in a mutually exclusive manner, J. Virol., 92 (2018), e00396-18.
    [77] M. P. Lythgoe, P. Middleton, Ongoing clinical trials for the management of the COVID-19 pandemic, Trends Pharmacol. Sci., 41 (2020), 363–382. doi: 10.1016/j.tips.2020.03.006
    [78] K. Sharun, R. Tiwari, J. Dhama, K. Dhama, Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence, Int. J. Surg., 82 (2020), 179–181. doi: 10.1016/j.ijsu.2020.08.038
    [79] RECOVERY Collaborative Group, Dexamethasone in hospitalized patients with covid-19: Preliminary report, N. Engl. J. Med., 384 (2020), 693–704. doi: 10.1056/NEJMoa2021436
    [80] T. Rhen, J. A. Cidlowski, Antiinflammatory action of glucocorticoids: New mechanisms for old drugs, N. Engl. J. Med., 353 (2005), 1711–1723. doi: 10.1056/NEJMra050541
    [81] M. Cornut, E. Bourdonnay, H. Thomas, Transcriptional Regulation of Inflammasomes, Int. J. Mol. Sci., 21 (2020), 8087. doi: 10.3390/ijms21218087
    [82] S. Christgen, D. E. Place, T. D. Kanneganti, Toward targeting inflammasomes: Insights into their regulation and activation, Cell Res., 30 (2020), 315–327. doi: 10.1038/s41422-020-0295-8
    [83] F. Chen, G. Jiang, H. Liu, Z. Li, Y. Pei, H. Wang, et al., Melatonin alleviates intervertebral disc degeneration by disrupting the IL-1\beta/NF-\kappaB-NLRP3 inflammasome positive feedback loop, Bone Res., 8 (2020), 1–13. doi: 10.1038/s41413-019-0078-3
    [84] H. Wu, C. Zhao, Q. Xie, J. Xu, G. Fei, TLR2-melatonin feedback loop regulates the activation of NLRP3 inflammasome in murine allergic airway inflammation, Front. Immunol., 11 (2020), 172. doi: 10.3389/fimmu.2020.00172
    [85] B. B. Mishra, V. A. K. Rathinam, G. W. Martens, A. J. Martinot, H. Kornfeld, K. A. Fitzgerald, et al., Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome–dependent processing of IL-1\beta, Nat. Immunol., 14 (2013), 52–60. doi: 10.1038/ni.2474
    [86] G. Guarda, M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Förster, ., Type Ⅰ interferon inhibits interleukin-1 production and inflammasome activation, Immunity, 34 (2011), 213–223. doi: 10.1016/j.immuni.2011.02.006
    [87] K. G. Lokugamage, A. Hage, M. de Vries, A. M. Valero-JImenez, C. Schindewolf, M. Dittmann, et al., Type Ⅰ interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV, J. Virol., 94 (2020), e01410-20.
    [88] C. Juliana, T. Fernandes-Alnemri, S. Kang, A. Farias, F. Qin, E. S. Alnemri, Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation, J. Biol. Chem., 287 (2012), 36617–36622. doi: 10.1074/jbc.M112.407130
    [89] J. S. Lolkema, D. Slotboom, The Hill analysis and co-ion–driven transporter kinetics, J. Gen. Physio., 145 (2015), 565–574. doi: 10.1085/jgp.201411332
  • This article has been cited by:

    1. Irshad Sikandar Jamadar, Krishna Kumar, Sher Afghan Khan, Ambareen Khan, Mohammad Nishat Akhtar, Elmi Abu Bakar, Quantum Pressure and Memory Effects in Cancer Modeling: A Fractional Calculus Neural Network Approach, 2025, 25901230, 106080, 10.1016/j.rineng.2025.106080
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(4764) PDF downloads(289) Cited by(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog